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Background: Cervical cancer among Black women is a major individual and public health 
concern. Despite advancements in medical technology and policy, disparities in cervical cancer 
diagnosis and mortality still exist between White and Black women, with Black women having 
higher rates of diagnosis (10.0 vs 7.1 per 100,000) and mortality (4.1 vs 2.0 per 100,000). 
Previous studies have focused heavily on barriers to obtaining cervical cancer screening among 
Black women and efforts to improve screening rates. Despite speculation by researchers that gaps 
in receipt of quality follow-up care may contribute to disparities, its role in disparate mortality 
rates between Black and White women has yet to be formally studied. 
Purpose: The goals of the present research were to (1) assess differences in Pap screening rates 
and (2) rates of adherence to recommended follow-up care after abnormal Pap results between 
Black and White women, (3) evaluate how specific factors of the Health Belief Model (HBM) 
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influence the decision-making process for obtaining Pap screening and (4) receiving 
recommended follow-up Pap care, and (5) evaluate the role of ethnic centrality as a factor in 
health decision-making.  
Results: Results indicated that HBM facets functioned similarly in predicting engagement in Pap 
screening and follow-up care, although there were differences in the influence of different facets 
by race. Ethnic centrality showed little applicable influence on adherence to follow-up care 
among Black women. An exploratory analysis revealed that doctor recommendation was the 
most influential factor predicting follow-up care use for both racial groups.  
Conclusion: The present study offers support for increased education and training on provider 
recommendation of appropriate follow-up care, as well as effective provider communication of 
results and services using messaging that appeals to the values and concerns of patients.  
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An evaluation of differences in motivations to receive cervical cancer screening and follow-up 
care between Black and White women 
  
Introduction and Background 
Cervical Cancer 
 What is Cervical Cancer? Cervical cancer occurs when malignant cells develop in the 
cervix, which is a structure of tissue that attaches the lower section of the uterus to the upper 
section of the vaginal canal (Center for Disease Control and Prevention [CDC], 2014). The 
cervix serves many functions, including acting as a physical barrier preventing sexually 
transmitted infections (STIs) from entering the uterus, altering the consistency of mucus 
production to permit or prohibit conception, and dilating to allow childbirth to occur or tissue to 
be expelled during menstruation.  
What is Human Papillomavirus? Cervical cancer most commonly results from infection 
by certain high-risk strains of Human Papillomavirus (HPV) that are sexually transmitted 
(Ramondetta, 2013; U.S. Preventive Services Task Force [USPSTF], 2018). HPV is the most 
commonly occurring STI in the United States, and accounts for an estimated 14.1 million of the 
20 million new STI diagnoses that occur each year (CDC, 2013). It is estimated that 80% of 
Americans will have contracted HPV in their lifetime (American Sexual Health Association, 
2019), and 79 million Americans are currently infected with at least one strain of HPV (CDC, 
2016). Although HPV will largely be discussed throughout this project in terms of the potential 
for certain specific strains to negatively influence the cervix of cisgender women, people can 
become infected with HPV regardless of gender and HPV can influence many different body 
parts and systems.  
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While over 200 types of HPV exist, there are about 40 different strains that can infect the 
genitals (including the cervix, vagina, vulva, rectum, anus, penis, and scrotum), mouth, and 
throat (Planned Parenthood Federation of America [PPFA], 2018). Some of these HPV strains 
may cause warts to develop, while others may lead to problematic cell changes that can result in 
cancer over time. Of the types of cancer that can result from HPV infection, cervical cancer is 
the most commonly occurring (CDC, 2012). Other strains outside of these 40 types may cause 
warts to develop elsewhere on the body, such as on the hands and feet; however, these strains are 
not sexually transmitted and will not be the focus of this work. HPV 16 and 18 are the viral 
strains that are most often responsible for cervical cancer diagnoses, with HPV 16 accounting for 
50% and HPV 18 accounting for 20% of these diagnoses (Ramondetta, 2013). Still, there are 
other strains of HPV that have been linked to cervical cancer, and up to 40% of individuals who 
receive a cervical cancer diagnosis are infected with more than one strain of HPV (Ramondetta, 
2013). Most HPV infections are able to be cleared naturally by the body’s immune system over 
time; however, the high prevalence of HPV and likelihood of exposure to high-risk HPV strains 
indicate that those who have a cervix remain at risk for cervical cancer. Further, having a poorer 
immune system or becoming infected with more persistent strains of HPV can result in the body 
being unable to clear the virus(es) on its own, thus placing individuals at increased risk for 
developing cervical cancer. 
 How prevalent is cervical cancer? At one time, cervical cancer was the leading cause of 
cancer death among women in the U.S. (NIH, 1996). Though rates of diagnosis and mortality 
have fallen by around 75% over the past 50 years, cervical cancer is still the third most common 
gynecological malignancy among women in the United States (U.S. Cancer Statistics Working 
Group, 2015). Despite our advances, each year, around 12,000 individuals are diagnosed and 
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about 4,000 die from cervical cancer (CDC, 2014). In 2018, the estimated number of women in 
the U.S. who were living with cervical cancer was 289,696 (SEER, 2019). For 2019, the 
estimated number of new cases is 13,170 and the estimated number of deaths is 4,250 (National 
Cancer Institute [NCI], 2019). The median age at diagnosis is 50 years old; however, graphing 
cervical cancer diagnosis by age shows that women are most often diagnosed between the ages 
of 35-45 years old (NCI, 2019). 
How can cervical cancer be prevented?  
Abstinence. As HPV strains that affect reproductive organs are contracted through sexual 
contact, the easiest way to avoid HPV infection that may lead to cervical cancer is to practice 
abstinence. For those who are sexually active, it is suggested that barrier methods (e.g., latex 
condoms, dental dams) are used for protection against direct skin-to-skin contact that may result 
in transmission of the HPV virus (CDC, 2016).  
Vaccination. It is also widely suggested that individuals receive the HPV vaccination, 
which protects against the strains of HPV that most commonly result in cervical cancer (CDC, 
2012; Department of Health and Human Services [DHHS], 2013). The Gardasil 9 HPV 
vaccination specifically targets and protects against the two highest risk HPV strains involved in 
cervical cancer (HPV-16 and HPV-18), as well as five other strains that are linked with cancer 
(HPV-31, 33, 45, 52, and 58) and strains that cause the majority of cases of genital warts (HPV-6 
and HPV-11) (Bailey et al., 2018; Kahn, Lan, & Kahn, 2007; Merck Vaccines, 2019). The HPV 
vaccine is given in a series of two to three doses administered across a six- to 12-month span 
depending on age range (Bailey et al., 2018; Merck Vaccines, 2019; National Cancer Institute 
[NCI], 2014).   
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When first approved in 2006, vaccination was recommended for adolescent girls from 
11-12 years old (but could be administered beginning at the age of 9), and a similar 
recommendation was made for adolescent boys beginning in 2011 (NCI, 2014). Since then, 
recommendations have expanded even further. As of August 2019, the CDC recommends that 
vaccination occur before an individual reaches 15 years of age (Meites et al., 2019). This practice 
is recommended for two reasons: (1) HPV vaccines result in a higher immune response in those 
who are of preteen or young teen age, and (2) the vaccine is more effective at preventing 
infection if the series is completed before an individual becomes sexually active (Bailey et al., 
2018). Still, recent numbers indicate that among those 11-13 years old, only 36% of girls and 
14% of boys have been vaccinated (Bailey et al., 2018). 
It is also recommended that catch-up doses be administered to men through age 21, as 
well as women and “certain special populations” (i.e., gay or bisexual men and those who have 
lowered immune systems) through age 26 (Bailey et al., 2018; Meites et al., 2019). The most 
recent update to these recommendations includes those in the 27-45 age range. Clinical trials 
have shown efficacy in preventing HPV infections, and the CDC now recommends that shared 
clinical decision-making between provider and patient be utilized to determine whether those 
falling within this age range would benefit from vaccination (Meites et al., 2019). For example, 
those who are not in a mutually monogamous sexual partnership and/ or have new sexual 
partners are at risk for acquiring a new HPV infection and may benefit from vaccination (Meites 
et al., 2019). Those who receive the vaccine after age 15 will receive a schedule of three doses, 
with the second dose occurring 1-2 months after the first, and the third occurring 6 months 
following the second dose (Meites et al., 2019).   
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Cervical Cancer and HPV Screening. Medical advances have significantly reduced both 
cervical cancer diagnosis and mortality rates among those with a cervix, by allowing cancer to be 
detected at its earliest stages though Papanicolaou (Pap) smear testing (Parrish, 2016; 
Surveillance, Epidemiology, and End Results [SEER], 2019). During a Pap smear, a sample of 
cells is collected from the cervix by a medical professional and sent off to a medical lab to be 
evaluated for cell changes that indicate cancerous or pre-cancerous conditions. While Pap smears 
test for abnormal cell developments that result from HPV infection, they do not test for the HPV 
viruses themselves. HPV testing, on the other hand, does detect the presence of the HPV virus, 
which can develop into abnormal cell changes (i.e., cervical dysplasia) in the future that may 
ultimately result in the formation of cancerous cells.  
It is currently recommended that 21-29 year olds with a cervix obtain Pap testing at 3-
year intervals as long as results remain normal (USPSTF, 2018). It is suggested that those aged 
30-64 years old obtain either a Pap test at 3-year intervals, receive high-risk HPV testing every 3 
or 5 years, or receive both Pap testing and high-risk HPV testing every 5 years (American 
College of Obstetrics & Gynecology [ACOG], 2016; USPSTF, 2018). Current recommendations 
also state that if those aged 65 and older have had a history of normal results for the previous 10 
years, they may be able to stop testing (USPSTF, 2018). However, this particular guideline has 
recently been called into question after research has surfaced showing significant rates of 
cervical cancer diagnosis after age 65 (Dilley, O’Donnell, Smith, Bae, & Huh, 2018). In this 
work, data from the SEER and National Cancer databases were used and showed that between 
18.9-19.7% of cervical cancer diagnoses from 2000-2014 had been among women above the age 
of 65 (Dilley et al., 2018). For these and other reasons, screening practices and intervals should 
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be based on individuals’ circumstances and health history, and should be part of an ongoing plan 
of care between an individual and their medical provider. 
Screening recommendations are different from those previously listed for those who are 
at a higher risk of developing cervical cancer, such as those with a history of cervical cancer; 
those who are HIV positive or immunosuppressed; and those with a history of exposure to DES 
(diethylstilbestrol) while in utero (Vegunta Files, & Wasson, 2017). [DES is a synthetic form of 
estrogen that was prescribed to some pregnant women between 1938-1971 with the intention of 
preventing miscarriages or premature deliveries; however, it was later found that DES use early 
on in pregnancy could cause reproductive issues in the fetus (American Cancer Society, 2015).] 
People who are at higher risk for cervical cancer, such as those who fall into the above groups, 
may require more frequent Pap testing. Current recommendations instruct these individuals to 
consult with their provider about their specific medical history in order to discern the appropriate 
timetable for Pap testing given previous Pap results and other risk factors (ACOG, 2016). 
The significant reductions in cervical cancer diagnosis and mortality rates over the last 
five decades have been largely attributed to the development of effective Pap testing, HPV 
testing, and the modification of screening guidelines (Ramondetta, 2013). This is because even 
after an HPV virus has been contracted, it can take years or even decades for the viral infection 
to transition to the point of cervical dysplasia or develop into cervical cancer. There are typically 
no signs or symptoms of infection until years after contraction of the virus (CDC, 2016); 
therefore, routine Pap testing is particularly effective at catching cell changes early on and 
reducing the window of opportunity for the cell changes to persist unknowingly into cancer 
development.  
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Types of Abnormal Pap Results.  
There are a variety of abnormal Pap results that one can receive, which reflect a range in 
severity of abnormal cells or cervical dysplasia. 
ASC-US. The result that reflects the lowest level of severity is ASC-US (Atypical 
Squamous Cells of Undetermined Significance). This result indicates that abnormal cells have 
been detected on the surface of the cervix, but these cells may or may not be dangerous. ASC-US 
results are generally considered to be very mild, as they can also indicate other noncancerous 
causes, such as infections or inflammation (NCI, 2019).  
LSIL. LSIL (Low-grade Squamous Intraepithelial Lesion) refers to finding mild dysplasia 
(i.e., slightly abnormal cells) on the surface of the cervix. Because LSIL is caused by strains of 
HPV, it is considered to be more serious than ASC-US; however, it is common for the body to 
clear LSIL on its own without treatment (NCI, 2019). Still, it is possible for LSIL to become 
cancerous and spread. CIN I stands for Cervical Squamous Intraepithelial Neoplasia 1, and is 
defined in the same way as a LSIL result; however, CIN results are found when a cervical biopsy 
is taken (NCI, 2019). Because these results mean the same thing, LSIL and CIN I results are 
grouped together when appropriate.  
ASC-H. ASC-H (Atypical Squamous Cells – Cannot exclude High-Grade Lesion) results 
indicate the presence of abnormal squamous cells present in the tissue on the outer part of the 
cervix. These results may be a sign of more serious results (namely, HSIL), which may develop 
into cervical cancer over time if not treated. More testing may be needed to clarify diagnosis of 
cells when this result is received (NCI, 2019) 
HSIL. A type of moderate or severe dysplasia that is found on the surface of the cervix is 
referred to as a High-Grade Squamous Intraepithelial Lesion (HSIL). Abnormal cells in this 
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category can range from looking somewhat to very abnormal, and if no treatment is received 
then these cells may become cancer and spread to nearby healthy tissue (NCI, 2019).  
CIN II. Cervical Squamous Intraepithelial Neoplasia II (CIN II) results indicate that a 
cervical biopsy has been done and abnormal cells have been found on the surface tissue of the 
cervix. While this is not a cancer diagnosis, the result does refer to high-grade or moderate 
dysplasia and it may develop into cancer if treatment is not received. Appropriate treatment for 
this diagnosis may include cryotherapy, laser therapy, Loop Electrosurgical Excision Procedure 
(LEEP), or cone biopsy to remove or destroy abnormal tissue (NCI, 2019). Each of these 
treatment options are described in further detail in the next section.   
CIN III. Severely abnormal cells that are found on the surface of the cervix through the 
completion of a cervical biopsy are referred to as Cervical Squamous Intraepithelial Neoplasia 
III (CIN III). This result indicates high-grade or severe dysplasia, and is also sometimes referred 
to as Stage 0 Cervical Carcinoma in Situ (NCI, 2019). The treatment options for this diagnosis 
are the same as those for CIN II.  
AGC. A result of Atypical Glandular Cells (AGC) refers to abnormal cells found on the 
inner part of the cervix or the lining of the uterus. This result may be a sign of cancer, or could 
indicate the presence of other serious medical conditions (NCI, 2019). More testing may be 
needed to determine the source and significance of this result.  
AIS. Adenocarcinoma In Situ (AIS) results refer to atypical glandular cells, as well. This 
result indicates a pre-cancerous condition where these abnormal cells are currently localized to 
surface-level cervical tissue but could lead to an invasive adenocarcinoma if left untreated (NCI, 
2019).  
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Options after Abnormal Pap Results.  
If results from a Pap screening test come back as abnormal, but do not show that the 
patient currently has cervical cancer, there are methods of treatment designed to prevent the 
progression of the abnormal or precancerous cells into cancerous cells. These methods may be 
used individually or in combination in order to aid the healthcare provider in diagnosing cell 
changes with more specificity and potentially removing the abnormal cells.    
Diagnosis of Cervical Dysplasia. There are various methods that providers use to 
diagnose (or rule out) specific types or categorizations of cervical dysplasia. One method is a 
colposcopy. When colposcopies are performed, a specific microscope (i.e., colposcope) is used 
to examine the cervix with increased magnification so that the provider may evaluate the 
existence and type of cervical dysplasia based on the appearance of cells (The American College 
of Obstetricians and Gynecologists [ACOG], 2015). A provider may decide that in addition to 
the colposcopy, it would be advantageous to perform a cervical biopsy. During a cervical biopsy, 
a large cluster of cells that appear to be abnormal are collected from the surface of the cervix and 
sent to a lab to be assessed. A provider may also decide that endocervical curettage should be 
performed, which involves collecting clusters of abnormal cells from the inside of the cervical 
canal for further analysis (ACOG, 2015).  
Treatment of Cervical Dysplasia. There are two types of methods used for treatment once 
a diagnosis of the presence of precancerous cells is made: excisional treatments and ablation 
treatments. Excisional treatments consist of either a LEEP (Loop Electrosurgical Excision 
Procedure), which is the most common treatment used and involves using electrical current 
running through a wire loop to remove the part of the cervix with abnormal cell growth; or 
conization, where a cone-shaped portion of the cervix containing abnormal cells is removed 
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(ACOG, 2016). Ablation treatments, on the other hand, consist of either cryotherapy, where the 
abnormal cells are frozen and naturally detach; or laser therapy, where the tissue is destroyed 
using a focused beam of light (ACOG, 2016).  
Often, once treatment is administered, more frequent Pap and/ or HPV testing is 
recommended in order to follow up more closely on any subsequent cervical changes. 
Conversely, some types or stages of cervical dysplasia do not require treatment, as they may 
consist of more minor cell changes that the body may be able to clear up on its own (e.g., results 
indicating ASC-US, LSIL, or CIN I). Still, more frequent Pap and/ or HPV testing is typically 
recommended when this is the case, to monitor any new developments and catch any additional 
changes early on.  
Health Disparities in Cervical Cancer Diagnosis and Mortality 
 Despite the overall reduction of cervical cancer diagnoses and mortality that has been 
seen in recent decades, disparities still exist between White and Black women. The American 
Cancer Society (2016) reports that Black women experience higher rates of cervical cancer 
diagnosis than White women (10.0 vs 7.1 per 100,000 women), as well as double the rate of 
mortality (4.1 vs 2.0 per 100,000 women, respectively; American Cancer Society, 2016). 
However, more recent work that accounts for personal history of hysterectomy indicates the 
existence of even more severe disparities, and reports mortality rates of 10.1 vs 3.2 per 100,000 
women among Black and White women, respectively (Beavis, Gravitt, & Rositch, 2017). 
Although adjusted diagnosis rates are not reported, this work suggests that disparities in 
mortality rates had previously been underestimated by 44%. To put these new statistics into 
perspective, the authors compared the adjusted cervical cancer mortality rates to global rates, and 
found that the mortality rate among White women mirrored that found in other developed nations 
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(e.g., Europe, Australia/ New Zealand, Japan) at 3.3 per 100,000 women, while rates for Black 
women were in-line with those of less developed nations (e.g., all of Africa and Asia, not 
including Japan) at 9.8 per 100,000 (Beavis et al., 2017). Although Black women are more likely 
than any other racial/ethnic group to die from cervical cancer in the U.S., prior work has shown 
that Black women remain largely unaware of their increased rates of risk (Parrish, 2016).  
 Pap Screening. Disparities in diagnosis and mortality persist even as disparities in Pap 
screening behavior have narrowed, with Black women now obtaining Pap screening at rates that 
are equal to those of White women (American Cancer Society [ACS], 2016). Still, much of the 
research focused on reducing racial disparities in cervical cancer diagnosis and mortality 
continue to be aimed at increasing Pap screening behaviors of Black women (Ackerson, 2010; 
Bazargan, Bazargan, Farooq, & Baker, 2004; Bellinger, Millegan, & Abdalla, 2015; Strohl et al., 
2015; Weragoda et al., 2016). Both qualitative and quantitative studies have discussed various 
factors that result in non-adherent Pap screening behaviors among Black women, including 
socioeconomic status (SES; Bellinger et al., 2015; Weragoda et al., 2016), lack of adequate 
insurance coverage (Bellinger et al., 2015), knowledge about cervical cancer (Strohl et al., 2015), 
poor patient-provider communication and relationships (Ackerson, 2010; Bazargan et al., 2004), 
and ethnic identity (Bellinger et al., 2015). 
Low SES and lack of insurance coverage result in decreased access to screening, with 
some women relying on free or reduced-cost screening programs or opting to delay their care 
(Bellinger et al., 2015). Other studies have even noted that rates of cervical cancer incidence and 
mortality within some low-income communities in the U.S. come close to mirroring those rates 
documented in developing nations (Kahn et al., 2012; Jemal et al., 2013). Lack of knowledge 
about the causes of cervical cancer, how it can be prevented, and the use of Pap tests to screen 
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for it have each been related to lower rates of screening among Black women (Bellinger et al., 
2015; Strohl et al., 2015).  
As previously stated, studies have also found that many Black women are unaware of 
their increased risks related to cervical cancer and the need to obtain screening (Bazargan et al., 
2004). Patient-provider relationships have been thoroughly studied, and results have shown that 
receiving suggestions to receive screening and receiving health education from providers is a 
significant predictor of screening behavior (Johnson, Mueller, Eliason, Stuart, & Nemeth, 2016; 
Tracy, Schluterman, & Greenberg, 2013). Along with this, effective communication, trust, and 
the presence of shared decision-making between the patient and their provider have all been 
related to higher rates of screening (Ackerson, 2010; Bazargan et al., 2004; Bellinger et al., 
2015).  
Various provider interventions and culturally-focused health campaigns developed 
specifically to target Black women have been employed to encourage increased screening; 
however, mortality rates have not been significantly reduced (Parrish, 2016). These efforts may 
have positively influenced Pap screening rates over time, though, as it is currently reported that 
Black women now have equal rates of Pap screening to White women (ACS, 2016). However, it 
stands to reason that barriers other than those related to access to and utilization of Pap screening 
must remain, as Black women have been found at the time of cancer diagnosis to be older and to 
have a more advanced stage of cancer than White women even despite having roughly equal 
rates of Pap screening (Weragoda et al., 2016). The aforementioned differences in age and 
cancer stage at time of diagnosis have been found to be strong predictors of cervical cancer 
mortality in Black women (Brooks, Baguet, Gardner, Moses, & Ghosh 2000; Eggleston et al., 
2006); and though it has not been formally studied, it has been suggested that these differences 
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likely result from receiving no follow-up care or follow-up care of poor quality after receiving 
abnormal Pap test results (Benard et al., 2012; Brandt et al., 2006; DeSantis, Naishadham, & 
Jemal, 2013; Horner et al., 2011; Weragoda et al., 2016).  
Follow-Up Care as a Barrier. Some qualitative research has shown that lack of knowledge 
about follow-up care, the costs associated with such care, and the patient-provider relationship are all 
influential factors for ethnic minority women when making decisions about obtaining recommended 
follow-up care (Bellinger et al., 2015; Brandt et al., 2006; Coker, DeSimone, Eggleston, White, & 
Williams, 2009). Bellinger and colleagues (2015) noted that Black women reported little recollection 
about the follow-up care recommended by their provider, as well as limited access to follow-up care 
services that were recommended after they received their abnormal Pap results. Other research has 
suggested that the quality and appropriateness of treatment following abnormal Pap results may 
contribute to the racial disparities seen in survival rates, as ethnic minority women often do not share 
the same level of access to high quality health care that White women do (Hicks, Yap, Matthews, & 
Parham, 2006; Weragoda et al., 2016). Despite these speculations, the role of receipt of follow-up 
care in the disparate cervical cancer mortality rates between Black and White women has yet to be 
formally studied.  
Disparities based on socioeconomic status. Socioeconomic status (SES) has been 
implicated as a root cause of health disparities in cervical cancer diagnosis and mortality rates 
(Weragoda et al., 2016). SES can and has been operationalized and discussed in various forms 
within the literature. However, in relation to healthcare systems and service use, it is most often 
discussed within the frame of affordability and access, not just to health care, but to high quality 
health care. Consideration is often given to the ability to pay for services out of pocket, the 
availability of social aid programs focused on provision of health care services, and access to 
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health insurance coverage. A particularly important aspect of access to health insurance coverage 
is access to high-quality health insurance coverage (i.e., the ability of individuals to not be under-
insured), as access to low-quality insurance results in people having insurance coverage by title, 
but still not possessing the ability to afford the health care services that they need.  
Prior work has shown that people are more likely to forego health care services–including 
preventive services–if they lack any form of health insurance coverage, which is a behavior that 
has been documented as subsequently resulting in poorer health outcomes (Kaiser Commission 
on Medicaid and the Uninsured, 2006). Literature shows that those who are of lower income and 
who lack health insurance coverage possess decreased access to Pap screening, with some 
women being forced to rely on free or reduced-cost screening programs to obtain necessary care 
or delaying their care altogether (Bellinger et al., 2015; Weragoda et al., 2016). A study 
conducted by Garfield, Licata, & Young (2014) that collected a nationally representative sample, 
showed that only 33 percent of individuals who were uninsured reported receiving preventive 
screenings, compared to 67 percent of individuals who had Medicaid coverage, and 74 percent of 
those who had private health insurance. Thus, health insurance coverage – and quality health 
insurance coverage, specifically – can serve as a significant factor when considering access to 
care. Unfortunately, access to any health coverage, especially access to quality health coverage, 
in the United States is largely dependent upon level of employment and rate of income. This 
means that, in some sense, quality of insurance coverage and SES are inextricably linked in this 
country.  
The role of the PP(ACA) in working to reduce health disparities.  
The Patient Protection and Affordable Care Act (PPACA) may represent a step in a new 
direction, as a chief aim of the legislation has been to equalize the quality of insurance coverage and 
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access to services irrespective of SES or class standing. The passage of the ACA has resulted in 
increased access to preventive cancer screenings, such as cervical cancer screening, for many 
individuals (ASPE, 2015). One major accomplishment of the ACA has been the expansion of access 
to health insurance coverage – through efforts like Medicaid expansion and the provision of federal 
subsidies – to millions of U.S. citizens who did not previously have coverage. While this change has 
resulted in increased access to care for a substantial number of people, the establishment of Essential 
Health Benefits (i.e., healthcare services that insurance providers are now required by law to cover 
with no additional cost-sharing responsibilities for patients) have expanded access to care even 
further (ASPE, 2015). Included in these Essential Health Benefits are preventive cancer screenings, 
such as cervical cancer screening. This means that individuals are now supposed to have access to 
these preventive screening services at no out-of-pocket cost to them (Kaiser Family Foundation, 
2013), which has the potential to significantly reduce barriers to certain preventive care. Altogether, 
this legislation reflects the desire for a cultural shift away from treatment and toward prevention of 
health issues.  
However, the ACA is not without its faults. The final draft of the ACA legislation did not 
include the initially proposed requirement that states expand their Medicaid coverage to those living 
at or below 138 percent of the federal poverty level. Instead of including a blanket requirement for all 
states to expand, the decision to expand, Medicaid coverage using these or other guidelines was left 
up to individual states, and financial incentives were offered for states that decided to expand. 
Although 37states (including Washington D.C.) out of 50 have accepted Medicaid expansion (as of 
November 2019), 14 have yet to do so, leaving many of the poorest citizens residing within these 
states in a health coverage gap (Kaiser Family Foundation, 2019). Citizens residing in the coverage 
gap are deemed ineligible for Medicaid coverage, but are also unable to qualify for federal subsidies 
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to offset health insurance costs within the marketplace, since individuals must be situated between 
138 and 400 percent of the federal poverty level to qualify for this assistance.  
Another significant limitation is that the ACA does not specify diagnostic testing or 
treatments as Essential Health Benefits. Specifically considering cases of cervical cancer prevention, 
this means that while preventive cancer screenings may be free, any tests that are required to confirm 
or formally diagnose precancerous or cancerous cell changes, as well as any treatments for such 
abnormal cell changes or cervical cancer at any stage, are still subject to patient cost-sharing. Thus, 
patients may be required to pay co-pays, co-insurance rates, or deductibles in order to access these 
vital services which are aimed at reducing the chance that their condition would continue into 
advanced stages. Because such diagnostic tests and treatments can range in cost and may require the 
care of a specialist, lack of high quality health insurance coverage for these services has the power to 
severely limit access to life-saving follow-up care and treatment, and ultimately contribute to the 
health disparities previously noted. 
The Role of Ethnic Centrality in Cervical Cancer Disparities 
 Qualitative work completed by Bellinger and colleagues (2015) evaluated the factors that go 
into deciding whether to obtain a Pap smear among Black women in the American south. A major 
theme that emerged in the group discussion was that of ethnic identity. Interestingly, the specific role 
of ethnic identity was variable between women and served as both a protective and predictive factor 
for cervical cancer care. Some of the women who were interviewed viewed Pap testing as a rite of 
passage into womanhood, and many felt that it was their cultural responsibility as Black women to 
promote their own health and that of their families and social networks (Bellinger et al., 2015). These 
women specifically discussed the need to maintain their own health so that they may be present and 
able to care for others, and some extended this idea to the responsibility of educating others about the 
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importance of screening (Bellinger et al., 2015). However, for others, cultural identity was 
prohibitive of receiving screening. Some women described the script of the “Strong Black Woman,” 
in that they were expected to sacrifice their own health and well-being for that of others around them, 
which resulted in personal delay or avoidance of care (Bellinger et al., 2015). Still others discussed 
the importance of womanhood and motherhood, and reported that fears about the potential for 
abnormal results to indicate the need for a hysterectomy or other fertility-compromising treatment 
prevented them from seeking care in the first place (Bellinger et al., 2015). The role of ethnic identity 
in cervical cancer prevention and care this appears to be an important one that warrants further 
explanation.  
Theoretical Framework: The Health Belief Model (HBM) 
The Health Belief Model (HBM) (depicted in Figure 1) is used to explain how 
individuals make choices regarding their health (Janz & Becker, 1984), and has been used to 
evaluate decision-making related to preventive service use such as cancer screening behavior 
(University of Twente, 2016). Additionally, this model has been used in previous work to predict 
cancer screening behaviors specifically among Black women (Hoyo et al., 2005; Johnson, Mues, 
Mayne, & Kiblawi, 2008). This model is comprised of five dimensions: (1) susceptibility, (2) 
severity, (3) benefits, (4) barriers, and (5) cues to action, which are outlined below and in figure 
1 (National Cancer Institute [NCI], 2005). 
1. Susceptibility refers to perceptions of risk related to contracting a certain condition, 
2. Severity refers to beliefs about how serious an issue or condition is, or how strongly it 
may affect one’s health or wellness, 
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3. Benefits refer to perceptions about how positive engaging in a certain health action may 
be, or how effective the health action may be in reducing susceptibility or severity of a 
condition, 
4. Barriers refer to beliefs about the negative aspects, outcomes, or costs (e.g., physical, 
psychological, etc.) of engaging in the health action, and 
5. Cues to action refer to any factors that may trigger engagement in a health action or a 
desire to engage in the health action 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The Health Belief Model (modified slightly from Glanz, Rimer, & Lewis, 2002, p.52).  
The Health Belief Model and Prevention 
This model has been applied to various populations and a plethora of health behaviors, 
and has been used to address public health concerns (Conner & Norman, 1996; Chamption & 
Skinner, 2016), including preventive health behaviors such as cancer screening, vaccination 
uptake, and birth control use behaviors, as well as clinical use behaviors, such as physician visits 
(Joseph et al., 2014; University of Twente, 2016; Yarbrough & Braden, 2001). The dimensions 
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of the health belief model are substantially supported by empirical evidence as significant 
predictors of individuals’ engagement in various health behaviors (Janz & Becker, 1984). 
However, in practice, the Health Belief Model is often broken down and used to assess one or 
more of the above components on their own rather than testing the influence of the full model on 
a health behavior outcome of interest (Crepaz & Marks, 2002; Yarbrough & Braden, 2001).  
Previous research evaluating ethnic disparities in cervical cancer screening and mortality 
have studied the influence of individual components of the HBM, such as: perceived risk of 
susceptibility in relation to screening behavior (Parrish, 2016), the role of cervical cancer 
knowledge in perceptions of susceptibility and severity (Strohl et al., 2015) and benefits and 
barriers to screening (Bellinger, 2014), and cues to action provided by targeted health campaigns 
(Wong et al., 2013; Wong, AbuBakar, & Chinna, 2014) or healthcare providers (Bazargan, 2004; 
Bellinger et al., 2015) on Pap screening uptake. Though these dimensions have been evaluated 
separately in relation to cervical cancer screening behavior, the HBM (in combination with path 
modeling techniques) provides a strong framework through which these dimensions can be 
evaluated simultaneously to determine how these factors influence one another and the outcomes 
of interest. In the present study, each of these HBM framework dimensions were included in 
analyses predicting engagement in Pap screening and the innovative study of receipt of follow-
up care after receiving an abnormal Pap result. Ethnic centrality additionally served as a 
moderator under the dimension of ‘cue to action’ predicting receipt of recommended cervical 
cancer follow-up care (see Figure 5 for the full model used). 
Present Research 
 The goals of the present research were to (1) assess differences in Pap screening rates 
between Black and White women, (2) examine rates of adherence to recommended follow-up 
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care following abnormal Pap results between Black and White women, (3) evaluate how specific 
factors of the HBM influence the decision-making process for obtaining Pap screening, (4) 
evaluate how these factors influence the decision-making process for receiving follow-up Pap 
care, and (5) evaluate the role of ethnic centrality as a moderator in health decision-making.  
 Hypothesis 1a-b: In line with prior research (American Cancer Society [ACS], 2016), it 
was hypothesized that (a) Black women would have rates of Pap screening and abnormal Pap 
results that were similar to those of White women. As an extension of previous findings, it was 
additionally hypothesized that (b) Black women would have lower rates of follow-up care 
utilization after receiving abnormal Pap test results.  
  Hypothesis 2a-f: Drawing on findings from previous research evaluating attitudes, 
knowledge, and experiences with Pap screening and follow-up care (Bazargan, 2004; Bellinger, 
2015; Parrish, 2016), it was hypothesized that the degree to which various dimensions of the 
HBM influence decisions to receive or avoid Pap screening would differ between Black and 
White women (See Figure 2). Specifically, it was hypothesized that: (a) demographic variables 
for Black and White women would be similarly related to Pap screening, such that age would be 
negatively related to Pap screening (i.e., younger women would be more likely to obtain 
screening), and education and SES would be positively related to Pap screening (i.e., those who 
were more educated and of a higher SES would be more likely to engage in Pap screening) 
regardless of race; (b) insurance status would be negatively related to perceived barriers and this 
relationship would be stronger for Black women; (c) perceived susceptibility and (d) perceived 
severity would be positively related to Pap screening and show a stronger influence among Black 
women; (e) perceived barriers would be negatively related to receiving Pap testing and this 
relationship would be stronger for Black women, and (f) perceived benefits of receiving Pap 
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screening would be positively related to Pap screening and this relationship would be stronger 
for White women. 
 
 
Figure 2. A path model using the components of the Health Belief Model of behavior to depict 
the hypothesized relationships between various factors and receipt of Pap screening. This model 
was run separately for Black and White women.  
 
Hypothesis 3a-g: In building off of hypothesis 2, it was expected that the degree to 
which the dimensions of the HBM influence receipt of follow-up care following an abnormal 
Pap result would differ among Black and White women. More specifically, it was hypothesized 
that: (a) demographic variables for Black and White women would be similarly related to receipt 
of follow-up care, such that younger women, those who are less educated, and those who are of 
lower SES would be less likely to engage in follow-up care after an abnormal Pap result 
regardless of race; (b) insurance status would be negatively related to perceptions of barriers, 
positively related to follow-up care use, and this relationship would be stronger for Black 
women; for both Black and White women, higher levels of severity of an abnormal Pap result as 
conveyed by a medical provider would be related to increased perceptions of (c) susceptibility 
and (d) severity of cervical cancer; (e) perceptions of barriers would be negatively related to 
receiving follow-up care after an abnormal Pap result and this relationship would be stronger for 
Black women; (f) perceptions of benefits of receiving follow-up care would be positively related 
to receiving such care and this relationship would be stronger for White women. It was also 
hypothesized that while the directions of the effects will mirror those found for Pap screening, 
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(g) the influence of perceived barriers and benefits would be more strongly related to decisions 
to obtain follow-up care.  
 
 
Figure 3. A path model using the components of the Health Belief Model of behavior to depict 
the hypothesized relationships between various factors and receipt of follow-up care. This model 
was run separately for Black and White women.  
 
Hypothesis 4a-c: Based on previous qualitative work (Bellinger et al., 2015), it was 
hypothesized that strong ethnic centrality would serve as a significant moderator for Black 
women between perceptions of (a) susceptibility and (b) severity of cervical cancer and the 
decision to obtain follow-up care, but would not significantly influence decision-making among 
White women. Specifically, it was expected that for Black women, those with stronger ethnic 
centrality would be less likely to receive recommended follow-up care (See Figure 4).  
 
Figure 4. Moderation model showing that the relationship between perceptions of susceptibility 
and severity and receiving subsequently recommended follow-up care is moderated by the 
salience of Black women’s ethnic centrality. 
 
Additionally, it was expected that (c) ethnic centrality would serve as a significant 
moderator between perceptions of susceptibility and severity of cervical cancer and receipt of 
recommended follow-up care for Black women in the larger HBM model, but that ethnic 
centrality would not serve as a significant moderator among White women in this decision-
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making process. More specifically, it was expected that all of the hypothesized relationships 
from H3 will be present; however, it was further hypothesized that for Black women, identifying 
more closely with one’s ethnicity would weaken the relationship between cervical cancer threat 
perceptions and the likelihood of obtaining recommended follow-up care after receiving an 
abnormal Pap result, thus resulting in a lower likelihood of obtaining such care (See Figure 5). 
 
Figure 5. A modified version of the path model used to test H3, depicting the additional pathway 
of ethnic identity as a moderator between perceived threat and receipt of follow-up care. This 
model was run separately for Black and White women. 
 
Method 
Participant Recruitment 
Amazon Mechanical Turk (MTurk) is a crowdsourcing website where individuals who 
are referred to as “workers” complete web-based tasks (usually, but not always) in exchange for 
monetary compensation. In MTurk, workers complete “Human Intelligence Tasks” (HITs) set up 
by “requesters” (who are the employers) that can range from providing feedback on media 
advertisements to passage translation to handwriting transcription to product rating, and more 
(Azzam & Jacobson, 2013; Berinsky, Huber, & Lenz, 2012). More recently, MTurk has also 
gained the interest of researchers as a platform for conducting research with human subjects.  
The use of MTurk has several strengths. One of the most important strengths that the 
platform has in relation to this study is the ability to easily reach people who are located all 
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across the country. A significant amount of the research evaluating disparities in Black women’s 
receipt of cervical cancer screening and treatment care have focused on the experiences of Black 
women living in the American south (Bellinger et al., 2015; Carter, 2008; Freeman & Wingrove, 
2005; Prabhu Das, 2005; Weragoda et al., 2016; Zhan & Lin, 2014). While these experiences are 
certainly important to the conversation, a goal of the present work was to evaluate the 
experiences of Black women from diverse geographic locations within the U.S. Another benefit 
is the reduced risk of the presence of social desirability bias among respondents (Brinkerhoff, 
2016).  
Moreover, the platform has successfully been used for cancer disparity research. 
Although much cancer disparity research (including work specifically focused on racial 
disparities) relies on data from large population surveys such as the National Breast and Cervical 
Cancer Early Detection Program (NBCCEDP; Dalzell et al., 2015; Tangka et al., 2015; White & 
Wong, 2015), Health Information National Trends Survey (HINTS; Blake et al., 2015; Price, 
Koshiol, Kobrin, & Tiro, 2011; Zhao & Nan, 2016), the Behavioral Risk Factor Surveillance 
System (BRFSS; Chen, Kessler, Mori, & Chauhan, 2012; Gandhi et al., 2015; Herrera et al., 
2012), and the National Health Interview Survey (NHIS; Forney-Gorman & Kozhimannil, 2016; 
Prince et al., 2011; Solomon, Breen, & McNeel, 2008; Sirovich & Welch, 2004), a substantial 
portion of more recent work has turned to MTurk data collection to gain more insight into 
individual experiences related to cancer prevention behaviors. MTurk has been used to evaluate 
knowledge, perception, and intention specifically related to cervical cancer screening and 
prevention (Porter, Amin, & Bednarczyk, 2018), online cancer information-seeking (Chae, 
2015), and attitudes and well-being of cancer survivors (Arch & Carr, 2015). Additionally, the 
crowdsourcing site has been used to evaluate other similar research topics, such as knowledge 
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and attitudes related to ovarian cancer (Carter, DiFeo, Bogie, Zhang, & Sun, 2014), lung cancer 
(Zide et al., 2015), breast cancer screening (Yeh, Schnur, Margolies, & Montgomery, 2015), 
sexual behavioral factors (Beymer, Holloway, & Grov, 2018), and infertility (Farrell, Brennan, & 
Lanham, 2018).  
In other countries, work related to cervical cancer screening has been completed using 
crowdsourcing sites outside of MTurk. For instance, work being conducted among populations in 
Britain (Marlow, Ferrer, Chorley, Haddrell, & Waller, 2018) and comparing samples in Australia 
and the U.S. (Schmid et al., 2017) used Qualtrics and Survey Monkey, respectively, for data 
collection. This may be related to the fact that the majority of MTurk workers are from the U.S. 
(75%) or India (16%), with only 0.7 percent of MTurk workers living in Britain, and even fewer 
living in Australia (Difallah, Filatova, & Ipeirotis, 2018). Still other studies surveying cancer-
related perceptions and behaviors in countries such as Canada (Duffet-Leger, Letourneau, & 
Croll, 2008) and Korea (Kim, 2014) have relied on the collection of data from university 
samples.  
A strength of MTurk is that it offers the ability to collect data from hundreds of 
participants in the span of a few hours (Litman, Robinson, & Abberbock, 2017). While previous 
research using MTurk has been able to collect decently sized samples of women (Carter et al., 
2014; Porter et al., 2018; Yeh et al., 2015) and cancer survivors (Arch & Carr, 2015; Chae, 
2015), a potential concern for the present project was the ability to collect data from self-
identified Black women. The U.S. Census Bureau population estimates for 2017 show that Black 
citizens comprise slightly over 13 percent of the population. However, Black women make up 
just over seven percent of the U.S. population (U.S. Census Bureau, 2017). Since the proportion 
of Black women in the country is so small relative to the proportion of White women, it was 
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anticipated that there would be more difficulty involved in recruiting the amount of Black 
women needed to establish power for the study analyses.  
While the use of MTurk is unlikely to provide the same level of access as in-person study 
recruitment might, it does offer the ability to collect Black women from geographically diverse 
locations at a rate that appears to be higher than some other crowdsourcing platforms. Schmid 
and colleagues (2017) did not report demographic information related to race; however, Marlow 
and colleagues (2018) reported that 8.3 percent of their Qualtrics sample identified as Black and 
73 percent identified as White. Interestingly, a study evaluating attitudes towards cervical cancer 
screening recommendations in the U.S. that used Qualtrics for data collection reported a far 
larger sample of White participants (82%), although they did not break down the participation of 
other racial groups beyond categorization as “Non-White” (Gerend, Shepherd, Kaltz, Davis, & 
Shepherd, 2017). MTurk workers fluctuate in their participation on the site; however, previous 
work has shown that MTurk can be used to collect samples that are more racially diverse than 
Qualtrics (Beymer et al., 2018), social media recruitment, and university samples (Casler, Bickel, 
& Hackett, 2013). Additionally, some of the previously mentioned studies have been able to 
recruit Black women at a rate that is higher than the U.S. Census figures for Black women in the 
population (Farrell et al., 2018; Yeh et al., 2015).  
Because MTurk was not originally developed to meet the needs of social science 
researchers, a newer platform developed with the intention of serving researchers, TurkPrime, 
was used (Litman et al., 2017). TurkPrime links to requesters’ MTurk accounts and is designed 
to sample the same pool of MTurk workers; however, TurkPrime offers additional controls that 
allow researchers to collect data more efficiently, with less biased data, and at a lower cost. One 
of the benefits of this platform is the addition of a control to automatically assign qualifications. 
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This control allows researchers to reduce the risk of multiple survey completions by the same 
person, by assigning a “qualification” to workers after they complete the survey. This 
qualification assignment will result in workers who have previously completed the study not 
being able to access it again in the future.  
TurkPrime also provides a control called “microbatch” which allows researchers to set 
small batch collections to open at pre-determined times throughout the day. Bias in participant 
characteristics based on the day of the week and time of day that data collection batches are 
released has been noted, as certain types of people in certain areas of the country are more likely 
to be logged onto MTurk at certain times (Litman et al., 2017). The addition of this feature aids 
in the reduction of bias in sampling, since batches can be set up beforehand to be released at 
various points throughout various days. Perhaps the most beneficial control that TurkPrime 
offered for this study was the ability to “restart” a batch. Work by Chilton and colleagues (2010) 
has shown that participation in MTurk tasks drops by 70 percent after the first 24 hours after 
posting. The “restart” control allows requesters to refresh their data collection batch so that it 
appears at the top of the HIT list again. This control has been found to substantially improve 
participant engagement with and completion of tasks (Litman et al., 2017).  
Sample & Procedure 
A national, geographically-representative convenience sample was collected via MTurk 
for the current study. A survey was administered through this survey platform to cisgender 
women across the United States who were between the ages of 21 and 65. Data were collected 
from January until May of 2019. A total of 4,293 surveys were submitted by workers. After 
reviewing each submission, data from 2,330 participants (54.27%; 1,171 White women and 
1,159 Black women) were retained. The remainder of the submissions were excluded as a result 
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of issues such as quality assurance failures, participant errors in the form of incomplete or 
duplicate submissions, or multiple submissions emanating from the same IP address (See table 1 
below for full exclusion data). 
Table 1.  
Reasons for participant elimination from dataset 
Reason  
Participants excluded* 
n (%)** 
HIT submitted with fake code or no code  529 (26.95) 
Failed at least 3 quality assurance items 440 (22.41) 
Participant failed identity requirements (either indicated gender/ 
race/ age value that did not permit inclusion) 
329 (16.76) 
Duplicate submission by the same MTurk worker 231 (11.77) 
IP showed location outside of the U.S. 230 (11.72) 
Multiple attempts were shown attached to the same IP address 209 (10.65) 
Errors and/ or incoherent free-responses appeared in survey  147 (7.49) 
*Reasons listed for participant elimination from dataset are not mutually exclusive 
**Percentages taken as a portion of the overall 1,963 participants removed from the dataset 
 
An advertisement was posted on the MTurk website in the form of a HIT (Human 
Intelligence Task), which is a single task that MTurk workers have the option to complete. The 
description of the study in the advertisement indicated that survey items pertained to perceptions, 
experiences, and use of preventive reproductive health services. If workers were interested in 
completing the study then they could open the HIT, and they would be directed to the consent 
form for the study (see Appendix A for the full consent form). This consent form detailed the 
purpose of the study, included an overview of the topics included, and explained that the data 
collected from them would remain anonymous and confidential. Participants were also informed 
that the study would take roughly 30 minutes to complete, and that they would be compensated 
$0.75 upon successful completion, which is slightly above the average rate of compensation for 
this platform (Arch & Carr, 2017).  
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If individuals chose to participate, then they were directed via a link to the online survey 
in Qualtrics. Before accessing the full survey, participants completed a short pre-screening that 
collected part of their demographic information and determined their eligibility for participation 
based on the inclusion/exclusion criteria listed below. If participants did not meet the inclusion 
criteria for the study, then they were notified that they were not eligible to complete the full 
study and were directed out of the survey without compensation. 
Inclusion/exclusion criteria: Only self-identified cisgender women were recruited for this 
study. Inclusion was also limited to women between the ages of 21 and 65, due to the cervical 
cancer screening guidelines provided by the U.S. Preventive Services Task Force that 
recommend routine screening for the duration of this age range (USPSTF, 2018). Only 
participants who self-identified primarily as Black or White were able to participate in the study. 
Because MTurk workers are majority White (77%; Sawyer, 2016), separate HITs were created in 
order to recruit an equal number of Black and White women, and to ensure that recruitment of 
White women was paced equally alongside the speed of recruitment of Black women. One of the 
HITs included a filter within their demographic pre-screening survey that excluded anyone who 
did not identify as a Black woman, while the other had a filter to exclude anyone who did not 
identify as either a Black or White woman.  
Screening and informed consent procedures: Due to the online nature of this study, a 
waiver of documentation of informed consent was acquired in favor of electronic consent; 
therefore, participants were directed to an informed consent page that provided details of the 
study and their participation. Participants were required to indicate that they had read this 
consent form and wished to participate in the study in order to progress to the survey pre-
screener. Participants were informed via the consent document that certain demographic 
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characteristics were required to participate in the full study, and that they would be required to 
respond to a brief set of demographic questions before proceeding to the actual study survey. 
Participants were not informed of the desired demographic characteristics (i.e., age range, 
gender, and race requirements) before their completion of the demographic questions. 
After providing responses to the demographic survey, respondents who did not meet the 
inclusion criteria for participation in the study were informed of this and were not allowed to 
proceed, while respondents who did meet the inclusion criteria for the study were allowed to 
continue. The latter group was then able to participate in the rest of the study via completion of 
online questionnaires, which took approximately 30 minutes. Compensation was provided to 
participants upon successful completion of the study via the MTurk payment mechanism 
(automatic deposit to their account). Participants were informed via the consent document that in 
order to receive compensation for their participation, they must correctly respond to seven out of 
ten quality assurance questions (seven quantitative and 3 qualitative open response) that were 
placed randomly throughout the study. Successful participants were paid $0.75 upon successful 
completion of the study. Participants were also required to enter the same six-digit code into both 
the Qualtrics survey and MTurk HIT page in order to receive compensation. Once the codes 
were matched across online platforms and quality assurance items were checked for correctness, 
compensation was authorized.  
Both MTurk and Qualtrics operate through secure servers, and the only identification of 
the participant was present in the identification value assigned to the participant by MTurk. IP 
addresses were collected initially as a quality control measure to ensure participants had not 
submitted duplicate entries, but were removed from the dataset once data quality had been 
evaluated, and thus were not stored with the data. Because no identifying information was stored, 
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participation in the study remained anonymous. All study procedures were approved by the 
Institution Review Board (IRB) at Virginia Commonwealth University prior to data collection. 
Power Analysis 
Although 2,330 of the 4,293 submissions were initially retained for analyses, an 
additional 82 participants (45 White women and 37 Black women) were removed from the 
dataset. These 82 participants indicated that they had undergone a hysterectomy wherein their 
cervix had been removed, which meant that they would not need to obtain Pap screening and 
thus should not be included in analyses. The final sample size included 2,248 individuals (1,125 
White women and 1,123 Black women).   
Post hoc power analyses were run separately for chi square and moderation analyses 
using G*Power software (Faul, Erdfelder, Buchner, & Land, 2009). Power analyses for chi 
square analyses by race showed that (1) for the outcome of ever receiving abnormal Pap results 
with the participants in the sample who reported ever receiving Pap screening (n=2,008), it was 
determined that this sample size was sufficient to detect a small effect (0.1) at 0.94 (94%), (2) for 
the outcome of receiving recommended follow-up care including only participants who ever 
reported an abnormal Pap result and had a medical provider recommend they receive follow-up 
care (n=624), the sample size was sufficient to detect a small effect (0.15) at 0.93 (93%), and (3) 
for the outcome of receiving recommended follow-up care for more severe abnormal Pap results 
including only participants who ever reported a more severe abnormal Pap result and had a 
medical provider recommend they receive follow-up care (n=116), the sample size was sufficient 
to detect a moderate effect (0.35) at 0.93 (93%). 
In evaluating power for moderation analyses, it was determined that for analyses 
including only Black women (n=294), the sample size was sufficient to detect a small effect 
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(0.05) at 0.97 (97%). Moderation analyses including only White women (n=366) were 
determined to be powered to detect a small effect (0.15) at 0.99 (99%).   
Because software is not available to calculate post hoc power for path models, a priori 
power analyses were utilized to calculate power for each of the hypothesized path models using 
the a priori structural equation modeling power calculator created by Soper (2017). A power 
analysis for the theorized H2 model predicting Pap screening behavior that included 5 latent 
variables and 32 observed variables, a desired power level of 0.90 (90%), an error probability 
level of 0.05, and an anticipated effect size of 0.10 showed that a sample size of 2,008 was 
needed in order to detect small effects, and that a minimum of 269 participants were needed in 
order to test the model structure. Thus, the sample size of 2,248 participants was determined to 
provide adequate power at 0.90 to test for small effects.  
A power analysis for the theorized H3 model predicting utilization of follow-up care and 
included 6 latent variables and 37 observed variables, a desired power level of 0.90 (90%), an 
error probability level of 0.05, and an anticipated effect size of 0.18 showed that a sample size of 
629 was needed in order to detect small-medium sized effects, and that a minimum of 227 
participants were needed in order to test the model structure. Thus, the sample size of 660 
participants was determined to provide adequate power at 0.90 to test for small-medium level 
effects.  
A power analysis for the theorized H4 model predicting utilization of follow-up care and 
included 7 latent variables and 42 observed variables, a desired power level of 0.90 (90%), an 
error probability level of 0.05, and an anticipated effect size of 0.18 showed that a sample size of 
660 was needed in order to detect small-medium level effects, and that a minimum of 200 
participants were needed in order to test the model structure. Thus, the sample size of 660 
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participants was determined to provide adequate power at 0.90 to test for small-medium level 
effects.  
Measures 
Demographics. Participants provided information such as age, gender, race, ethnicity, 
sexual orientation, relationship status, educational attainment, employment status, household 
income level, number of dependents, and their state of residence (See Appendix B for full study 
questionnaire). Gender was asked to ensure that participants who identified as anything other 
than a cisgender woman were excluded from the study, and age was asked primarily to ensure 
that participants were between the ages of 21 and 65.  
The household income level, number of dependents, and state of residence were used to 
calculate participants’ standing as a percentage of the federal poverty level (FPL). Percentage of 
the federal poverty level was calculated using the 2019 poverty guidelines provided by the US 
Department of Health and Human Services, where household size for each participant was 
multiplied by the poverty guideline for their state of residence (ASPE, 2019). If participants did 
not provide their state of residence, the poverty guidelines for the 48 contiguous states and the 
District of Columbia were used. 
Health Insurance Information. In order to gain an understanding of participants’ 
insurance status, questions were posed about the consistency of their health insurance coverage 
during the previous year and the type of insurance plan that they have. The item assessing 
consistency of health insurance coverage during the previous year was a modified version of the 
item used by Geisler and colleagues (2006), and includes the following response options: (1) “I 
was not insured at all in the past year,” (2) “I was insured for 1-6 months out of the last year, (3) 
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“I was insured for 7-11 months out of the last year,” and (4) “I was insured for all 12 months of 
the last year.”  
Health insurance plan type was assessed at a broad level of public versus private 
insurance, consistent with other studies (Culwell & Feinglass, 2007; Smith & Medalia, 2014). 
Private insurance plan types include the following: (a) a plan through an employer, (b) federal 
government insurance (for federal employees), (c) a plan through the government exchange/ 
Marketplace, (d) coverage through a parent’s plan, or (e) coverage through a university plan. 
Public insurance plan types include: (a) military insurance (Tricare), (b) Medicaid/ state program 
insurance, (c) Medicare, and (d) veteran benefits. Participants also had the option to respond 
“I’m not sure.” 
Perceived Barriers. Perceived barriers were assessed using a measure of barriers 
specifically related to cervical cancer screening. The “barriers” subscale of the Health Belief 
Model Scale for Cervical Cancer and Pap Smear Test developed by Guvenc and colleagues 
(2010) was used. This subscale included 14 items measured using a 6-point Likert scale ranging 
from “strongly disagree” to “strongly agree,” and assessed perceptions of various types of 
barriers (e.g., tangible financial- and resource- based barriers, emotional barriers) related to 
obtaining cervical cancer screening. For the overall sample, the reliability of this this subscale 
was α = .85 (see Table 2 for reliability values by race). An example item for this scale is “I have 
other problems more important than having a Pap smear test in my life.” A 13-item modified 
version of this scale was used to assess perceptions of barriers related to obtaining cervical 
cancer follow-up care following an abnormal Pap result, and the same 6-point Likert scale was 
used. Reliability for this measure was α = .83 (see Table 2 for reliability values by race). For this 
scale, the item “I am too old to have a Pap smear test regularly” that was present in the perceived 
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barriers measure for Pap screening was removed, rather than re-worded to reflect follow-up care. 
An example item for this scale is “I am afraid to have follow-up diagnostic tests done for fear of 
a bad result.” 
Perceived Benefits. Perceived benefits were assessed using a measure of benefits 
specifically related to cervical cancer screening derived from another subscale of the Health 
Belief Model Scale for Cervical Cancer and Pap Smear Test (Guvenc, Akyuz, & Han Acikel, 
2010). The “benefits” subscale included 5 items and was measured using a 6-point Likert scale 
ranging from “strongly disagree” to “strongly agree.”  The reliability of this scale was α = .73 
(see Table 2 for reliability values by race). An example item for this scale is “Having regular Pap 
smear tests will decrease my chances of dying from cervical cancer.” A 4-item modified version 
of this scale was used to assess perceptions of benefits related to obtaining cervical cancer 
follow-up care following an abnormal Pap result. Reliability for this measure was α = .79 (see 
Table 2 for reliability values by race). An example item from this measure is “I think that having 
diagnostic tests done after abnormal Pap results is a good way for cervical cancer to be 
diagnosed early.” 
Perceived Susceptibility. Another subscale established by Guvenc and colleagues (2010) 
that included 3 items assessing perceptions of susceptibility related to developing cervical cancer 
was used within models for both Pap screening behavior and receipt of follow-up care following 
receipt of an abnormal Pap result. This scale used the same 6-point Likert scale as above. For 
this sample, the reliability of this measure was α = .92 (see Table 2 for reliability values by race). 
An example item for this scale is “I feel I will get cervical cancer sometime during my life.” 
Perceived Severity. To evaluate perceptions of how strongly a cervical cancer diagnosis 
might influence their health, the “seriousness” subscale of the Health Belief Model Scale for 
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Cervical Cancer and Pap Smear Test developed by Guvenc and colleagues (2010) was used. 
Participants responded to 7 items using the same 6-point Likert scale as above. The reliability of 
this scale was α = .80 (see Table 2 for reliability values by race). An example item for this scale 
is “Problems I would experience with cervical cancer would last a long time.”  
Ethnic Centrality. Ethnic centrality was measured using a subscale that was adapted from 
the Multidimensional Inventory of Black Identity (Sellers et al., 1997). This 5-item ethnic 
centrality subscale is designed to assess the extent to which individuals’ ethnic label is central to 
how they define themselves. This subscale has been used across a range of ethnic groups of 
adolescent age, and has a good overall internal consistency (Fuligni, Witkow, & Garcia, 2005). 
For this sample, the reliability of this scale was α = .89 (see Table 2 for reliability values by 
race). Participants responded to items asking about their identification with their ethnic group 
and background using a 5-point Likert scale that ranged from “1-Strongly Disagree” to “5-
Strongly Agree.” An example item from this scale is “Being a part of my ethnic group is an 
important reflection of who I am.” 
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Table 2. 
Means, standard deviations, and Cronbach’s alpha coefficients for model predictors by group 
 
 
 
 
 
 
 Perceived 
Susceptibility 
to Cervical 
Cancer 
(3 items) 
Perceived 
Severity of 
Cervical 
Cancer 
(7 items) 
Perceived 
Barriers to Pap 
Screening 
(14 items) 
Perceived 
Benefits of Pap 
Screening 
(4 items) 
Perceived 
Barriers to 
Follow-Up 
Care 
(13 items) 
Perceived 
Benefits of 
Follow-Up 
Care 
(4 items) 
Ethnic 
Centrality 
(5 items) 
Mean (SD) 
α Reliability 
3.42 (3.21) 
.916 
19.72 (6.99) 
.798 
16.97 (10.96) 
.852 
14.18 (3.50) 
.728 
18.51 (11.29) 
.866 
14.25 (3.66) 
.792 
10.75 (5.19) 
.890 
Racial Group        
White  
3.99 (3.24) 
.919 
20.05 (6.28) 
.777 
17.12 (10.96) 
.855 
14.19 (3.18) 
.760 
18.44 (11.27) 
.866 
14.26 (3.35) 
.768 
8.26 (4.62) 
.892 
Black 
2.85 (3.08) 
.908 
19.39 (7.62) 
.815 
16.81 (10.96) 
.849 
14.18 (3.796) 
.745 
19.63 (11.65) 
.872 
14.23 (3.95) 
.813 
13.25 (4.47) 
.821 
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Severity of Abnormal Pap Test Results as Relayed by a Medical Provider. To evaluate the 
severity of participants’ abnormal Pap results, items were developed from concepts present in the 
Consumer Assessment of Healthcare Providers and Systems (CAHPS) survey, as well as some of 
the research literature (Bellinger et al., 2013; Nolan et al., 2014). Participants responded to 5 
items with response options of “Yes,” “No,” and “I don’t know.” An example item for this scale 
was “Did the doctor state that the results were potentially harmful to your health?” Response 
options were re-coded so that “Yes” received a score of 1, while “No” and “I don’t know” 
received a score of 0. A total score was then developed by adding the scores from each of the 5 
items, so participant scores ranged from 0-5. 
Cervical Care Health Behaviors and Results. Participants were asked to self-report their 
medical history related to cervical cancer services and related diagnoses. Individuals were asked 
to provide information about Pap screening behavior including whether they had ever had a Pap 
smear during their lifetime, if they had received a Pap smear during the previous 3 years, and 
how long ago they had received their last Pap smear. 
Participants were also asked to report whether they had received an abnormal result on 
their most recent Pap screening. For participants who indicated that they had not received an 
abnormal result on their most recent Pap, the question was broadened to ask whether they had 
ever received an abnormal Pap result. If participants had received an abnormal Pap result in 
either of these cases, they were asked to indicate what the official diagnoses for their abnormal 
Pap results were. Responses to these items were used to develop a variable describing 
experiences of lifetime abnormal Pap results and included data from 660 individuals who had 
experienced abnormal results.  
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If participants indicated that they had ever received an abnormal Pap result, they were 
asked to answer additional questions about whether a medical provider recommended they obtain 
additional follow-up diagnostic tests or treatment after receiving the abnormal Pap, which 
specific follow-up tests or treatments had been recommended, and whether they obtained the 
follow-up care recommended by their medical provider (See Appendix B for full questionnaire).  
Additional Medical History. Participants were asked to respond to various items 
evaluating their medical history outside of cervical cancer prevention care. Respondents were 
asked about previous HIV diagnosis and diagnosis of autoimmune disorders, exposure to DES 
while in utero, and previous cervical cancer diagnosis. Medical history including any of these 
would be likely to result in a doctor’s recommendation to receive more frequent Pap screening, 
and was helpful to factor in when determining the frequency at which participants should be 
screened (i.e., if more frequent than every 3 years would be likely).  
Additionally, because Pap smear testing requires the presence of a cervix, participants 
were asked whether they had a hysterectomy performed and whether their cervix was removed 
during this procedure. Thus, participants who reported having a hysterectomy where the cervix 
was removed (n=82) were removed from further analyses. 
Quality Assurance. In order to reduce random response rates and promote greater data 
quality, ten questions were placed throughout the survey as quality assurance items. Seven of 
these items were multiple response or true/ false items, and three were open-ended response 
items. Participants were notified in the informed consent document that if they failed to correctly 
answer seven out of ten of these items then they would not receive compensation. Participant 
data was removed for all individuals who failed seven out of ten of the quality assurance items.  
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Results 
Demographic Information 
 Sample demographic information is shown in Table 3. The ages of participants ranged 
from 21-64 years old, and the average age of participants was 35 years (SD = 10.16). An 
independent t test showed that there was a significant difference in age by racial group, though 
the means differed by less than two years. The sample also largely consisted of those who had 
received their Bachelor’s degree (35.7%) and who were employed full time (55.8%), with no 
significant differences based on racial group. There were, however, significant differences in 
insurance status during the previous year, with Black women being more likely to have not had 
insurance at all or to only have had insurance for 1-6 months out of the year, while White women 
were more likely to have had insurance for all 12 months out of the year.  
When compared to the 2015 state population estimates published by the U.S. Census 
Bureau, the current sample was geographically representative at r = 0.933, p<.001. There were 
significant differences in U.S. region of residence by racial group, with Black women being 
more likely to live in the South and White women being more likely to live in the Midwest or 
West; however, there were no significant racial differences among those living in the Northeast. 
 
 Table 3.    
Sample demographic characteristics 
 Black Women 
(n=1,123) 
White Women 
(n=1,125) 
 
Characteristic Means (SD)/ 
Percentages (n) 
Means (SD)/ 
Percentages (n) 
t/ Mann-Whitney z / 
x2 test values 
Age (Years) 34.15 (9.84) 35.79 (10.41) t (2246) = 3.832*** 
Income  54,428.65 
(54,322.521) 
65,912.25 
(56,977.19) 
Z = -7.036*** 
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Education    
Middle school 0.0 (0)  0.2 (2)  
x2 (6) = 10.354 (ns) 
GED 2.7 (30)  2.8 (31)  
High School 21.5 (242)  21.5 (242)  
Vocational School 6.4 (72)  7.0 (79)  
Associates Degree 19.3 (217)  16.3 (183)  
Bachelor’s Degree 36.4 (409)  35.0(394)  
Graduate Degree (Master’s, Doctorate) 13.6 (153) a 17.2 (194) b 
Employment Status    
Unemployed  25.0 (278)  25.4 (286)  
x2 (2) = 2.024 (ns) 
Employed part time 18.0 (200)  20.1 (226)  
Employed full time 57.1 (635)  54.5 (613)   
Insurance Status    
No Insurance at all in past year 12.1 (136) a 8.9 (100) b 
x2 (3) = 23.818*** 
Insured for 1-6 months 10.3 (115) a 6.3 (71) b 
Insured for 7-11 months 6.8 (76)  5.3 (60)  
Insured for all 12 months of past year 70.8 (793) a 79.5 (894) b 
Geographical Region    
Northeast 17.8 (200)  18.2 (205)  
x2 (3) = 78.170*** 
Midwest 15.5 (174) a 22.8 (257) b 
South 54.9 (616) a 38.0 (428) b 
West 11.8 (133) a 20.9 (235) b 
N = 2248 
SD = Standard deviation 
***p<.001, ns = not significant 
For analyses comparing multiple categories, columns with different superscripts (a,b) differ 
significantly (Bonferroni corrected) 
 
 Correlations were used to determine the extent to which ethnic centrality was related to 
age, education, and income level. Pearson correlations revealed that scores on ethnic centrality 
were not significantly related to age (r= -0.033, p=0.120), and were positively related to 
education (r=0.066, p<0.01). Spearman’s rho indicated that ethnic centrality was negatively 
related to level of income during the previous year (rs= -0.077, p<0.001). 
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Hypothesis 1a-b. 
 Pap screening. Chi square analyses were conducted to determine whether rates of Pap 
screening differed based on racial group (Table 4). There was a significant difference in lifetime 
Pap screening, with White women being more likely to have ever received a Pap screening in 
their lifetime. However, among women who had reported at least one lifetime screening, Black 
women were more likely than White women to have received screening within the previous three 
years, as well as the previous five years.  
Table 4. 
Differences in Pap screening based on racial group 
 Black Women 
n (%) 
White Women 
n (%) X2 
Pap Screening, lifetime a 982 (87.4) 1026 (91.2) 8.312** 
 
Of those who had ever had a Pap screening  
Pap Screening, last 3 years b 833 (84.8) 821 (80.0) 7.986** 
Pap Screening, last 5 years b 911 (92.8) 917 (89.4) 7.081** 
**p<.01 
a Analysis included all participants (n=2,248) 
b Analysis included those who reported ever having received a Pap smear (n=2,008) 
 
 Abnormal Pap results. A chi square analysis was also conducted to determine whether 
rates of abnormal Pap results differed based on racial group (Table 5). The analysis showed that 
there was a significant difference in receipt of abnormal results overall, with 29.9 percent of 
Black women and 35.7 percent of White women reporting receiving any abnormal result across 
their lifetime. Specific Pap results reported by participants are present in the table, as well, and 
show that the most commonly endorsed options across both racial groups were ASC-US 
(Atypical Squamous Cells of Undetermined Significance) and abnormal results where specific 
results of Pap screening were unknown. Black women were significantly more likely to report 
receiving an abnormal result of ASC-US, while White women were significantly more likely to 
report an abnormal result of HSIL (High-Grade Squamous Intraepithelial Lesion). 
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 Interestingly, Black women were significantly more likely to report that they never 
received their Pap results from their provider, and White women were significantly more likely 
to report that their Pap screening had returned an abnormal result before, but that they were not 
able to recall what the specific abnormal result was.  
Table 5. 
Differences in abnormal Pap results based on racial group 
 Totals 
n (%) 
Black Women 
n (%) 
White Women 
n (%) X2 
Any abnormal Pap result c 660 (32.9) 294 (29.9) 366 (35.7) 7.476** 
     
Differences in abnormal results by race d 
ASC-US 291 (44.0) 153 (52.0) a 138 (37.5) b 
21.279** 
Abnormal, but unsure of result 231 (34.9) 87 (29.6) a 144 (39.1) b 
LSIL 78 (11.8) 34 (11.6) 44 (12.0) 
ASC-H 21 (3.2) 11 (3.7) 10 (2.7) 
HSIL 17 (2.6) 3 (1.0) a 14 (3.8) b 
ACG 24 (3.6) 6 (2.0) 18 (4.9) 
     
Result of LSIL or more severe d 140 (21.2) 54 (4.8) 86 (7.6) 7.739** 
     
Never received Pap result c 53 (2.6) 33 (3.4) 20 (1.9) 3.888* 
*p<.05, **p<.01 
For analyses comparing multiple categories, columns with different superscripts (a,b) differ 
significantly (Bonferroni corrected) 
c Analysis included those who reported ever having a Pap smear (n=2,008) 
d Analysis included those who reported abnormal results (n=660) 
 
 Follow-up care. Further chi square analyses were used to evaluate differences in receipt 
of care following abnormal Pap results (Table 6). When taking into account all abnormal results 
of any severity level (i.e., lowest to highest severity included), White women were significantly 
more likely than Black women to report that their providers had recommended that they obtain 
some form of follow-up care after receiving their abnormal Pap results. However, if follow-up 
care had been recommended by a provider, Black and White women were equally likely to report 
obtaining at least some of the follow-up care that was recommended to them.  
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The same pattern emerged when the abnormal results with the lowest level of severity 
(i.e., ASC-US and abnormal but unsure of specific results) were removed, leaving only the more 
severe abnormal results (i.e., LSIL or above) to be analyzed. In fact, even more disparate rates of 
doctor recommendation were shown between the racial groups. Still, there were no significant 
differences based on racial group in rates of receipt of follow-up care when higher-level 
diagnostic testing (i.e., colposcopy, biopsy, LEEP, conization, cryotherapy, laser therapy, or 
follow-up with a specialist) that would be appropriate for these results had been recommended 
by providers. 
Table 6. 
Doctor recommendation of follow-up care and patient engagement after an abnormal Pap result 
 Totals 
n (%) 
Black Women 
n (%) 
White Women 
n (%) X2 
Of those who received any abnormal Pap result (n=660) 
Doctor recommended follow-up care 624 (94.5) 270 (91.8) 354 (96.7) 7.543** 
     
Of those who had a doctor recommend follow-up care (n=624) 
Individual received at least some 
doctor recommended follow-up care 
554 (88.8) 234 (86.7) 320 (90.4) 2.138(ns) 
     
Of those who reported a result of LSIL or more severe result (n=140) 
Doctor recommended follow-up care 116 (82.9) 38 (70.4) 78 (90.7) 9.650** 
     
Of those who had a doctor recommend follow-up care (n=116) 
Individual received at least some 
doctor recommended follow-up care 
105 (90.5) 33 (86.8) 72 (92.3) 0.889(ns) 
**p<.01 
 
Hypotheses 2a-f. 
 H2a-f were tested using path models that were designed using dimensions of the Health 
Belief Model to explain Pap screening behaviors. In the figure shown (figure 6), ovals indicate the 
unobservable “latent” variables, which included perceived susceptibility, perceived severity, 
perceived benefits, and perceived barriers. These variables were measured using multiple observed 
items, as indicated in the above section detailing measures used. Rectangles indicate the observed 
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variables, which were measured directly, and consist of demographic information and receipt of Pap 
screening.  
 
Figure 6. Theorized version of the Health Belief Model for H2a-f.  
 
The baseline model was first run with the entire sample included and without considering 
race as a factor, in order to determine good model fit for the sample as a whole. To ensure that the 
model was also a good fit for each racial group individually, two separate but equivalent baseline 
models were then run. When the full proposed HBM model predicting Pap screening during the 
previous three years was run, model fit was acceptable, with a chi square=7.888 (df=1, p=0.005), 
RMSEA (Root Mean Square Error of Approximation) =0.056, and a CFI (Comparative Fit 
Index) =0.995. However, while this model showed good fit for White women (x2(1)=2.037, 
p=0.154; RMSEA=0.031; CFI=0.999), it showed only acceptable model fit for Black women 
(x2(1)=6.692, p=0.010; RMSEA=0.072; CFI=0.991). The baseline model was re-run without 
nonsignificant paths emanating from demographic characteristic predictors and showed 
improved overall model fit (x2(12)=17.562, p=0.130; RMSEA=0.014; CFI=.0996), as well as 
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good fit for the groups of both White (x2(12)=10.127, p=0.605; RMSEA=0.000; CFI=1.000) and 
Black (x2(12)=15.252, p=0.228; RMSEA=0.016; CFI=0.995) women individually.  
 Once the model was determined to be a good fit for both groups individually, the 
configural model was run including both groups in order to establish a statistical baseline model 
for invariance analyses. This model maintained good fit across both groups (x2(24)=25.375, 
p=0.386; RMSEA=0.007; CFI=0.999), and still reflected a somewhat better fit for White women 
compared to Black women (individual chi square contributions: 9.515 and 15.862, respectively).  
The fully constrained model was then run with all remaining model paths constrained to 
be equal to test for invariance between groups. Model fit was reduced, but remained acceptable 
(x2(42)=110.773, p=0.000; RMSEA=0.038; CFI=0.948), and reflected worsened fit for both 
groups, although fit remained worse for Black women than White women (chi square 
contributions 62.628 vs 48.144, respectively). Further, the chi square difference test comparing 
the constrained model to the configural model was significant, reflecting that model invariance 
was not achieved (x2(18)=85.397, p=0.000).  
Modification indices for the constrained model were used to remove path constraints 
from the model, and indicated that paths from perceived barrier and benefit factors predicting 
Pap screening, as well as covariance paths between the factors of perceived benefits and 
perceived barriers, perceived susceptibility and perceived severity, perceived severity and 
perceived benefits, and perceived susceptibility and perceived barriers should be relaxed and 
able to vary between groups. These modifications were made and the invariance analysis was 
then repeated. This model showed improved fit overall (x2(36)=42.335, p=0.216; 
RMSEA=0.013; CFI=0.995), as well as for each individual group (x2 for White women=17.618, 
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x2 for Black women=24.716). Model invariance was also achieved with this model 
(x2(12)=16.959, p=0.151).  
However, in an effort to further improve model fit among Black women, the initial 
baseline model for each group was consulted to determine where other significant group 
differences might lie. Paths that were nonsignificant for either White or Black women in this 
baseline model were relaxed so that they were able to vary between groups, and the model was 
re-run. Nonsignificant paths only among White women included the ones between insurance 
status and perceived severity, as well as perceived susceptibility and Pap screening; while the 
nonsignificant paths among only Black women included those between education predicting 
perceived susceptibility, as well as age, federal poverty level (FPL) standing, and perceived 
benefits predicting engagement in Pap screening.  
Model invariance remained in this final model (x2(6)=4.059, p=0.669), and model fit was 
further improved overall (x2(30)=29.435, p=0.495; RMSEA=0.000; CFI=1.000), and for each 
group individually (x2 for White women=11.663, x2 for Black women=17.772). The r-square 
values showed that this final model explained 25.6% and 20.4% of the variance in Pap screening 
behavior during the previous three years for White and Black women, respectively. As depicted 
in figures 7.1-7.3, the model further showed that while paths from insurance status, perceived 
barriers, and perceived susceptibility predicting Pap screening, along with paths from age and 
insurance status predicting perceived barriers, and insurance status predicting perceived benefits 
were significant and able to be constrained to be equal across groups, many others varied.  
Paths from age, FPL standing, and perceived benefits predicting Pap screening were not 
significant for Black women, but had influence for White women. A similar pattern emerged for 
the path between education predicting perceptions of susceptibility to cervical cancer. 
48 
 
Conversely, the path from perceived susceptibility predicting Pap screening was not significant 
for White women, but had influence for Black women. The same pattern emerged for the path 
between insurance status predicting perceived severity of cervical cancer, and although the path 
between age predicting perceived severity was significant among White women, it remained 
more influential for Black women. 
Hypothesis Outcomes. Partial support was found for this collection of hypotheses. H2a 
found minimal support. For White women, age was negatively related to Pap screening, meaning 
that as age increased engagement in Pap screening decreased, and SES was positively related to 
Pap screening, such that as SES increased engagement in Pap screening increased, as well. 
However, age and education were not significant predictors of Pap screening receipt among 
Black women, and education was not a significant predictor of screening for either racial group, 
resulting in a lack of full support for this hypothesis.  
H2b was supported, as insurance status was negatively related to perceptions of barriers 
to obtaining Pap screening, and this relationship was more influential among Black women. For 
both groups, this result indicates that as duration of insurance coverage during the previous year 
increased, the perception of barriers to obtaining screening decreased.  
H2c was partially supported, with perceptions of susceptibility to cervical cancer being 
positively related to Pap screening, but only among Black women. Perceptions of cervical cancer 
severity were positively related to Pap screening behavior among both racial groups and 
reflected a stronger influence among Black women, which provided complete support for H2d. 
Partial support was also attained for H2e. Perceptions of barriers to screening were 
negatively related to engagement in Pap screening. Although present results indicated a slightly 
stronger relationship value for Black women, the influence of this path was closer to being equal 
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across the racial groups. H2f was supported, though, as perceptions of benefits to Pap screening 
positively predicted engagement in Pap screening, and this relationship was only significant 
among White women. 
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Figure 7.1. Path model showing the final invariant model for H2a-f. Line arrows represent significant constrained paths that did not 
show moderation by race. Dashed arrows represent paths that were relaxed/ moderated by race.  
*p<.05, **p<.01, ***p<.001, ns = not significant 
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Figure 7.2. Path model showing model paths that were significant for White women. Line arrows represent significant constrained 
paths that did not show moderation by race. Dashed arrows represent paths that were relaxed/ moderated by race.  
*p<.05, **p<.01, ***p<.001 
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Figure 7.3. Path model showing model paths that were significant for Black women. Line arrows represent significant constrained 
paths that did not show moderation by race. Dashed arrows represent paths that were relaxed/ moderated by race.  
*p<.05, **p<.01, ***p<.001 
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Hypotheses 3a-g. 
H3a-g were tested using path models that were designed using dimensions of the Health 
Belief Model to explain follow-up service use behaviors following receipt of an abnormal Pap result. 
This model is an extension of the path model used to evaluate H2a-f, and includes the addition of the 
variable of severity of an abnormal Pap result as conveyed by a medical provider. In the figure 
shown (figure 8), ovals indicate the unobservable “latent” variables, which consist of the severity of 
abnormal Pap results as relayed by a medical provider, perceived susceptibility, perceived severity, 
perceived benefits, and perceived barriers. These variables were measured using multiple observed 
items, as indicated in the above section detailing measures used. The rectangles indicate the observed 
variables, which were measured directly, and consist of demographic information and receipt of 
recommended follow-up care.  
 
Figure 8. Theorized version of the Health Belief Model for H3a-g.  
 
The theorized baseline model was first run with the entire sample of those who had reported 
ever receiving an abnormal Pap result included (n=660) and without considering race as a factor, in 
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order to determine good model fit for the sample as a whole. To ensure that the model was also a 
good fit for each racial group individually, two separate but equivalent baseline models were then 
run. When the full proposed HBM model predicting engagement in follow-up care was run, model fit 
was acceptable (x2(3)=14.283, p=0.003; RMSEA=0.076; CFI=0.955). While this model showed a 
good fit for Black women (x2(3)=4.142, p=0.247; RMSEA=0.036; CFI=0.988), it showed very 
poor fit for White women (x2(3)=13.874, p=0.003; RMSEA=0.100; CFI=0.933). 
The baseline model was re-run without paths that were nonsignificant among both groups 
(i.e., paths from insurance status predicting perceived susceptibility, perceived severity, and 
perceived benefits; and paths from FPL predicting perceived susceptibility, severity, benefits, 
barriers, and the receipt of follow-up care) and showed improved overall model fit 
(x2(6)=15.053, p=0.020; RMSEA=0.048; CFI=0.961), as well as good fit among both Black 
(x2(6)= 7.828, p=0.251; RMSEA=0.032; CFI=0.978) and White (x2(6)=13.402, p=0.371; 
RMSEA=0.058; CFI=0.951) women.  
After this model was determined to show good fit among both groups individually, the 
configural model was run including both groups to establish a statistical baseline model for 
invariance analyses. This model maintained good fit across both groups (x2(12)=21.352, 
p=0.455; RMSEA=0.049; CFI=0.961), although it did reflect better fit for Black women 
compared to White women (individual chi square contributions: 7.678 vs 13.674, respectively).  
The fully constrained model was then run with all remaining model paths constrained to 
be equal in order to test for invariance between groups. Model fit was slightly reduced, but 
remained acceptable (x2(36)=58.800, p=0.010; RMSEA=0.043; CFI=0.906), and reflected 
worsened fit that was roughly equal across both groups (x2 for Black women=29.244; x2 for 
White women=29.256). Further, the chi square difference test comparing the constrained model 
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to the configural model was significant, reflecting that model invariance was not achieved 
(x2(24)=37.148, p=0.042). 
Modification indices for the constrained model were used to determine that the addition 
of paths using severity of the result as relayed by a doctor to predict perceived benefits and 
barriers to follow-up care would improve model fit for White women. These paths were added to 
the model, were relaxed, and the invariance analysis was repeated. This model showed improved 
fit overall (x2(32)=44.708, p=0.067; RMSEA=0.035; CFI=0.947), and did show improved fit for 
White women (x2=18.341), although fit was not drastically improved for Black women 
(x2=26.367). Model invariance was achieved through these changes (x2(20)=23.356, p=0.272).  
In an effort to improve model fit for Black women, the initial baseline and constrained 
models were consulted to determine where other significant group differences might lie. Paths 
that were nonsignificant for either White or Black women (but not among both groups) were 
relaxed (i.e., paths from age predicting perceived susceptibility to cervical cancer and receipt of 
follow-up care; paths from education predicting perceived susceptibility, severity, and benefits, 
as well as receipt of follow-up care; a path from insurance status predicting perceived barriers to 
follow-up care; paths from perceived susceptibility to cervical cancer and benefits of follow-up 
care predicting receipt of follow-up care; and a path from severity of abnormal results as 
conveyed by a medical provider predicting perceptions of severity of cervical cancer). 
Not only was overall model fit improved (x2(23)=21.269, p=0.565; RMSEA=0.000; 
CFI=1.000), but model fit was stronger than in the original configural model, and showed 
improved fit for each group individually (x2 for Black women=12.674; x2 for White 
women=8.595). The r-square values showed that that this final model explained 17.2% and 
20.2% of the variance in follow-up service use after receiving an abnormal Pap result for Black 
56 
 
and White women, respectively. As depicted in figures 9.1-9.3, only 10 of the 24 originally 
hypothesized paths remained in the final model. Six of these paths were able to be constrained to 
be equal across groups (i.e., paths from age predicting perceptions of severity of cervical cancer; 
insurance status predicting perceived barriers to follow-up care; insurance status and perceived 
barriers to follow-up care predicting receipt of follow-up care; and severity of results as 
conveyed by a medical provider predicting perceived susceptibility to cervical cancer.  
The model additionally required that the four remaining paths be relaxed and able to vary 
between groups, and that two additional paths be added to the model. The final invariant model 
thus had 10 significant paths. The negative path from education level predicting perceived 
susceptibility to cervical cancer, as well as the positive path from perceived benefits predicting 
receipt of follow-up care were significant for White women but not for Black women. The added 
paths from severity of an abnormal Pap result as conveyed by a medical provider positively 
predicting perceived barriers and negatively predicting perceived benefits of follow-up care were 
also significant for White women but not among Black women. Conversely, positive paths from 
severity of an abnormal Pap result as conveyed by a medical provider predicting perceptions of 
severity of cervical cancer and from perceived susceptibility to cervical cancer predicting receipt 
of follow-up care were only significant for Black women. 
 Hypothesis Outcomes. Partial support was found for this collection of hypotheses, as 
well. H3a was not supported, as age, education, and SES were not significantly related to 
obtaining follow-up care for either racial group. However, age was found to significantly predict 
perceptions of cervical cancer severity and benefits of follow-up care for both racial groups, such 
that perceptions of cervical cancer severity and benefits to obtaining follow-up care decreased as 
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age increased. It was further found that education significantly predicted perceptions of cervical 
cancer susceptibility for White women, with perceptions decreasing as education level increased. 
H3b was partially supported, as insurance status was found to be negatively related to 
perceptions of barriers to follow-up care, and positively related to engagement in follow-up care 
after an abnormal Pap result. These results showed that as duration of insurance status during the 
previous year increased, perceptions of barriers to follow-up care decreased, and engagement in 
follow-up care increased. However, the influences of these relationships were roughly equal 
between racial groups.  
Full support was found for H3c, with severity of an abnormal Pap result as conveyed by a 
medical provider positively predicting perceptions of susceptibility to cervical cancer for both 
racial groups. Results reflected a positive relationship, such that as the conveyed severity of 
abnormal Pap results increased, perceptions of susceptibility to cervical cancer increased, as 
well. Conversely, severity as conveyed by a medical provider only positively predicted 
perceptions of cervical cancer severity among Black women, resulting in a lack of full support 
for H3d.  
Partial support was found for H3e. Perceptions of barriers to receiving follow-up care 
was negatively related to obtaining follow-up care for both racial groups. However, this 
relationship was not found to be more influential among Black women, as this path was 
constrained to be roughly equal across racial groups. H3f received support, with perceptions of 
benefits to receiving follow-up care after an abnormal Pap result being significantly, positively 
related to obtaining follow-up care among White – but not Black – women.  
Finally, only partial support was found for H3g. The influence of perceived benefits of 
follow-up care predicting follow-up care utilization (which was only significant for White 
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women) was stronger than that of the prediction of perceived benefits on Pap screening 
utilization in H2 (β=.287 vs β=.144, respectively), thus providing support for the hypothesis. 
However, although perception of barriers to follow-up care significantly, negatively predicted 
follow-up care utilization for both racial groups, the influence of perceived barriers predicting 
Pap screening utilization (H2) was much stronger for both groups, reflecting a β=0.160 decrease 
between the models for White women and a β=0.187 decrease for Black women between the two 
models.  
Additionally, although not originally part of the hypothesized model, modification 
indices suggested that two paths be added to improve the model. These newly added paths from 
severity of an abnormal Pap result as conveyed by a medical provider positively predicting 
perceived barriers and negatively predicting perceived benefits to obtaining follow-up care were 
significant for White women but not among Black women. 
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Figure 9.1. Path model showing the final invariant model for H3a-g. Line arrows represent significant constrained paths that did not 
show moderation by race. Dashed arrows represent paths that were part of the original theoretical model and were relaxed/ moderated 
by race. Bolded dashed arrows represent paths that were later added to the theoretical model and relaxed/ moderated by race.  
*p<.05, **p<.01, ***p<.001, ns = not significant 
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Figure 9.2. Path model showing model paths that were significant for White women. Line arrows represent significant constrained 
paths that did not show moderation by race. Dashed arrows represent paths that were part of the original theoretical model and were 
relaxed/ moderated by race. Bolded dashed arrows represent paths that were later added to the theoretical model and relaxed/ 
moderated by race.  
*p<.05, **p<.01, ***p<.001 
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Figure 9.3. Path model showing model paths that were significant for Black women. Line arrows represent significant constrained 
paths that did not show moderation by race. Dashed arrows represent paths that were relaxed/ moderated by race.  
*p<.05, **p<.01, ***p<.001 
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Hypotheses 4a-b. 
 To test hypotheses 4a-b, four moderation analyses were run. Product terms were created 
from the independent and moderator variables for each analysis. The first two analyses for H4a 
evaluated the hypothesized influence of ethnic centrality on the relation between perceived 
susceptibility to cervical cancer and receipt of recommended follow-up care. For both Black and 
White women, perceived susceptibility was not significantly related to receipt of follow-up care 
(β=0.153, p=0.164 vs. β= -0.184, p=0.084, respectively). Further, ethnic centrality was neither a 
significant moderator for this relationship (β=0.232, p=0.067 vs. β=0.033, p=0.732), nor a 
significant predictor for receipt of follow-up care (β=0.138, p=0.229 vs. β= -0.097, p=0.383) for 
either racial group.   
 The second set of analyses for H4b evaluated the hypothesized influence of ethnic 
centrality on the relation between perceived severity of cervical cancer and receipt of 
recommended follow-up care. The same pattern emerged. Again, for both Black and White 
women, perceived severity was not significantly related to receipt of follow-up care (β=0.119, 
p=0.517 vs. β=0.084, p=0.674, respectively). Ethnic centrality was also not a significant 
moderator between the variables (β=0.132, p=0.283 vs. β= -0.267, p=0.087), and it was not a 
significant predictor of receipt of follow-up care on its own (β=0.124, p=0.545 vs. β=0.366, 
p=0.134).  
 Although the moderations were not significant for either group, interesting findings did 
emerge. Results from these analyses indicated that ethnic centrality was significantly related to 
perceived susceptibility (βBlack= -0.616, p<0.001 and βWhite= -0.735, p<0.001) and perceived 
severity (βBlack= -0.908, p<0.001 and βWhite= -0.927, p<0.001) for both groups. 
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Hypothesis 4c. 
Hypothesis 4c was tested using path models that were an extension of those used to test 
H3a-g. The paths from the final invariant model used in H3a-g were used as a baseline to 
construct the model tested in H4c. Although the moderations in H4a-b were not significant in 
predicting follow-up service use behaviors, ethnic centrality was shown to be significantly 
related to perceptions of both cervical cancer susceptibility and severity. As a result of this 
finding, ethnic centrality was not added into the final model as a moderator, and was instead 
entered as a predictor of both perceived susceptibility and perceived severity. The final model is 
shown in figure 10, where ovals indicate the unobservable “latent” variables, including the 
severity of abnormal Pap results as relayed by a medical provider, perceived susceptibility, perceived 
severity, perceived threat, perceived benefits, perceived barriers, and ethnic centrality. These 
variables were measured using multiple observed items, as indicated in the above section detailing 
measures used. Similar to the previously tested models, the rectangles indicate the observed 
variables, which were measured directly, and consist of demographic information and receipt of 
recommended follow-up care.  
64 
 
 
Figure 10. Theorized version of the Health Belief Model for H4c (modified to include 
significant paths from the final invariant model of H3).  
 
As in previous analyses, the theorized baseline model from figure 10 was first run with the 
entire sample of those who had reported ever receiving an abnormal Pap result included (n=660) and 
without considering race as a factor, in order to determine good model fit for the sample as a whole. 
To ensure that the model was also a good fit for each racial group individually, two separate but 
equivalent baseline models were then run. When the full proposed HBM model predicting 
engagement in recommended follow-up care was run, model fit was good (x2(6)=10.469, p=0.106; 
RMSEA=0.034; CFI=0.981). This model showed acceptable fit for Black women (x2(6)=12.571, 
p=0.050; RMSEA=0.061; CFI=0.927), and showed good fit for White women (x2(6)=6.945, 
p=0.326; RMSEA=0.021; CFI=0.994). The configural model was then run including both groups 
to establish a baseline model for invariance analyses. This model maintained good fit across both 
groups (x2(12)=19.503, p=0.077; RMSEA=0.043; CFI=0.969), although it reflected better fit for 
White women compared to Black women (individual chi square contributions: 6.836 and 12.667, 
respectively).  
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The fully constrained model was then run with all model paths constrained to be equal in 
order to test for invariance between groups. Model fit was slightly reduced, but remained good 
(x2(41)=61.370, p=0.021; RMSEA=0.039; CFI=0.917), and reflected worsened fit for both 
groups, although fit remained worse for Black women (x2 for White women= 24.226; x2 for 
Black women= 37.144). Further, the chi square difference test comparing the constrained model 
to the configural model was significant, reflecting that model invariance was not achieved with 
the fully constrained model (x2(29)=41.867, p=0.048). 
The constrained model showed no significant modification indices through which the 
model could be improved. Therefore, in an effort to improve model fit for both racial groups, and 
among Black women in particular, the initial baseline and constrained models were consulted to 
determine where other significant group differences might lie. Paths that were nonsignificant for 
either White or Black were relaxed (i.e., paths from: age predicting perceived benefits to follow-
up care; education predicting perceived susceptibility to cervical cancer; severity of the abnormal 
Pap result as conveyed by a medical provider predicting both perceived severity of cervical 
cancer and benefits of follow-up care; perceived susceptibility to cervical cancer and benefits of 
follow-up care predicting use of follow-up care; and ethnic centrality predicting perceived 
severity of cervical cancer). 
Model invariance was achieved in this model (x2(20)=14.705, p=0.793). Model fit was 
improved overall (x2(32)=34.208, p=0.362; RMSEA=0.014; CFI=0.991), and was improved for 
each group individually (x2 for Black women=21.139; x2 for White women=13.069). However, in 
an effort to further improve model fit for Black women, one additional modification was made to 
the model. While modification indices and baseline models did not provide any additional insight 
into potential improvements to the model, after consulting previous literature and theory, a path 
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from ethnic centrality predicting perceived benefits of follow-up care was added and relaxed to 
vary across groups. This addition was based on literature showing that some Black women felt 
that cervical care could preserve their personal health and allow them to care for others, while 
others delayed care as a result of the “Strong Black Woman” schema, suggesting that they were 
expected to sacrifice their own well-being to care for others around them (Bellinger et al., 2015). 
These findings thus suggested that ethnic centrality may have an influence on the perception of 
potential benefits to obtaining follow-up cervical care services.  
This final model showed improved overall model fit (x2(32)=23.637, p=0.857; 
RMSEA=0.000; CFI=1.000), as well as improved model fit for each group (x2 for Black 
women=13.512; x2 for White women=10.125). The r-square values showed that that this final 
model explained 17.7% and 20.1% of the variance in follow-up service use after receiving an 
abnormal Pap result for Black and White women, respectively.  
As depicted in figures 11.1-11.3, 14 of the 23 hypothesized paths remained in the final 
model. Seven of these paths were able to be constrained to be equal across groups, and seven of 
the paths had to be relaxed and allowed to vary between groups. An additional path was later 
added to the model and was constrained to be equal, resulting in 15 significant paths in the final 
invariant model.  
Five of the constrained paths were the same as those present in the final invariant model 
for H3 (i.e., negatively related paths from age predicting perceptions of cervical cancer severity, 
insurance status predicting perceptions of barriers to follow-up care; and perceived barriers 
negatively predicting receipt of follow-up care; as well as positively related paths from insurance 
status predicting receipt of follow-up care; and the added path that was not present in the 
originally hypothesized model from severity of abnormal Pap results as conveyed by a medical 
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provider predicting perceptions of susceptibility to cervical cancer). In the present model, a 
previously relaxed path emanating from severity of abnormal Pap results as conveyed by a 
medical provider positively predicting perceptions of barriers to follow-up care was able to be 
constrained to be equal across groups. Additionally, two new positively related paths from age 
predicting engagement in follow-up care and ethnic centrality predicting perception of benefits to 
follow-up care were added to the model and able to be constrained to be equal across racial 
groups. 
 Five of the seven relaxed paths reflected the same paths seen in the final invariant model 
for H3. Three of these paths (i.e., two negatively related paths from education predicting 
perceptions of susceptibility to cervical cancer, and severity of abnormal Pap results as conveyed 
by a medical provider predicting perceived benefits to follow-up care; as well as one positively 
related path from perceived benefits predicting receipt of follow-up care) were significant for 
White women, while they were not significant for Black women. The other two paths (i.e., 
positively related paths from severity of abnormal Pap results as conveyed by a medical provider 
predicting perceptions of cervical cancer severity, and perceptions of susceptibility to cervical 
cancer predicting engagement in follow-up care) were significant among Black, but not White, 
women.  
The two remaining relaxed paths differed from the final invariant model present in H3. A 
path from age predicting perceptions of benefits to follow-up care that had previously been 
constrained to be equal in the final invariant model for H3 was relaxed in the current model, and 
represented a significant negative relationship only among White women. Additionally, the 
theorized path from ethnic centrality predicting perceptions of cervical cancer severity was 
unique to hypothesis 4, and showed a significant positive relationship among Black women only.  
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Hypothesis Outcomes. H4a and b were not supported, as all moderation analyses were 
nonsignificant. However, although ethnic centrality did not directly predict attainment of follow-
up care or moderate the relationships between perceived cervical cancer susceptibility or severity 
and attainment of follow-up care, this variable did emerge as a significant predictor of both 
perceived susceptibility and perceived severity. Thus, ethnic centrality was added into later path 
models as a predictor of both of these variables. 
Using the reconceptualized model that positioned ethnic centrality as a predictor rather 
than a moderator, H4c received little support. Although ethnic centrality did not significantly 
predict perceptions of susceptibility to cervical cancer for either racial group in the full model, it 
did predict perceptions of cervical cancer severity among Black women. However, this 
relationship showed that as feelings of ethnic centrality increased, perceptions of the severity of 
cervical cancer increased, rather than decreased.  
An additional finding that was not originally hypothesized was that of ethnic centrality 
positively predicting the perception of benefits to obtaining follow-up care for both racial groups. 
Although this relationship was more influential among Black women, higher levels of ethnic 
centrality were related to increased perceptions of benefits to obtaining follow-up care for both 
racial groups. 
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Figure 11.1. Solid line arrows represent significant constrained paths that did not show moderation by race. Dashed arrows represent 
paths that were part of the original theoretical model and were relaxed/ moderated by race. Bolded line arrows represent constrained 
paths that were later added to the theoretical model and did not show moderation by race. Bolded dashed arrows represent paths that 
were later added to the theoretical model and relaxed/ moderated by race.  
*p<.05, **p<.01, ***p<.001, ns = not significant 
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Figure 11.2. Path model showing model paths that were significant for White women. Line arrows represent significant constrained 
paths that did not show moderation by race. Dashed arrows represent paths that were part of the original theoretical model and were 
relaxed/ moderated by race. Bolded line arrows represent significant constrained paths that were not moderated by race. Bolded 
dashed arrows represent paths that were later added to the theoretical model and relaxed/ moderated by race.  
*p<.05, **p<.01, ***p<.001 
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Figure 11.3. Path model showing model paths that were significant for Black women. Line arrows represent significant constrained 
paths that did not show moderation by race. Dashed arrows represent paths that were relaxed/ moderated by race. Bolded line arrows 
represent constrained paths that were later added to the theoretical model and did not show moderation by race.  
*p<.05, **p<.01, ***p<.001 
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Exploratory Analyses. 
Exploratory analyses conducted as part of hypothesis 1 revealed that: (1) there were 
significant racial disparities in the reported rates of doctor recommendation to obtain follow-up care 
after receiving an abnormal Pap result, with White women being significantly more likely than Black 
women to report that their provider recommended follow-up care, and (2) the significant racial 
disparity found in rates of receipt of follow-up care were eliminated once receiving a doctor’s 
recommendation to obtain follow-up care was accounted for in analyses. As a result, another set of 
exploratory analyses were used to evaluate the role of provider recommendation to obtain follow-up 
care, if any, when added to the model tested in hypothesis 4c. The theoretical model tested is shown 
in figure 12, where ovals indicate the unobservable “latent” variables, and rectangles indicate directly 
measured “observable” variables, as in previous hypotheses.  
 
 
Figure 12. Theorized version of the Health Belief Model for exploratory analyses. This model 
reflects the model theorized for H4c, with the addition of doctor recommendation to obtain 
follow-up care.   
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As in the previous models, the theorized baseline model from figure 12 was first run with the 
entire sample of those who had reported ever receiving an abnormal Pap result included (n=660) and 
without considering race as a factor, in order to determine good model fit for the sample as a whole. 
To ensure that the model was also a good fit for each racial group individually, two separate but 
equivalent baseline models were then run. When the full proposed HBM model predicting 
engagement in recommended follow-up care was run, model fit was good (x2(5)=6.701, p=0.244; 
RMSEA=0.023; CFI=0.995). This model showed good fit for both Black  (x2(5)=5.221, p=0.390; 
RMSEA=0.012; CFI=0.998) and White (x2(5)=3.863, p=0.569; RMSEA=0.000; CFI=1.000) 
women individually, as well.  
The configural model was then run including both groups to establish a baseline model 
for invariance analyses. This model maintained good fit across both groups (x2(10)=9.066, 
p=0.526; RMSEA=0.000; CFI=1.000), and reflected only slightly better fit for White women 
compared to Black women (individual chi square contributions: 3.805 and 5.262, respectively).  
Next, the fully constrained model was run with all model paths constrained to be equal, in 
order to test for invariance between groups. Model fit was reduced, but remained good 
(x2(45)=76.160, p=0.003; RMSEA=0.046; CFI=0.904), and reflected worsened fit for both 
groups (x2 for White women=35.203; x2 for Black women=40.957). Further, the chi square 
difference test comparing the constrained model to the configural model was significant, 
reflecting that model invariance was not achieved with the configural model (x2(35)=67.094, 
p=0.001). 
Modification indices from the constrained model suggested that the path from doctor 
recommendation predicting perceived benefits be relaxed. This path, as well as some others that 
were shown in the initial baseline and constrained models to be nonsignificant for either White 
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or Black women, but not for both groups, (i.e., paths from age predicting perceived susceptibility 
to cervical cancer and benefits of follow-up care; education predicting perceived benefits; 
severity of abnormal Pap results as conveyed by a medical provider and ethnic centrality 
predicting perceived severity of cervical cancer and benefits of follow-up care; doctor 
recommendation to obtain follow-up care predicting perceived barriers to follow-up care; and 
perceived susceptibility to cervical cancer predicting receipt of follow-up care) were relaxed, and 
the model was re-run. 
Model invariance was achieved in this model (x2(24)=19.855, p=0.705). Model fit was 
improved overall (x2(34)=28.921, p=0.715; RMSEA=0.000; CFI=1.000), and showed 
improvement for each group individually (x2 for Black women=16.554; x2 for White 
women=12.368). R-square values showed that that this final model explained 47.4% and 36.0% 
of the variance in follow-up service use after receiving an abnormal Pap result for Black and 
White women, respectively. 
 As depicted in figures 13.1-13.3, 17 of the 29 originally hypothesized paths remained in 
the final model. Eight of these paths were able to remain constrained to be equal across groups, 
and nine of the paths had to be relaxed and able to vary between groups. Constrained paths for 
the current invariant model include seven of the same constrained paths present in the final 
invariant model for H4c (i.e., three negatively related paths from age predicting perceptions of 
cervical cancer severity; insurance status predicting perceived barriers to obtaining follow-up 
care; and perceived barriers predicting receipt of follow-up care; as well as four positively 
related paths from insurance status predicting receipt of follow-up care; severity of abnormal Pap 
results as conveyed by a medical provider predicting perceptions of susceptibility to cervical 
cancer and barriers to follow-up care; and ethnic centrality predicting perceived benefits of 
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obtaining follow-up care). The theorized path from doctor recommendation positively predicting 
receipt of follow-up care was unique to this exploratory analysis, and was additionally able to be 
constrained as equal across both racial groups. 
Relaxed paths for the current model included seven paths that were present in the final 
invariant model for H4c, as well. Four of these paths (i.e., three negatively related paths from age 
predicting perceptions of benefits to follow-up care; education predicting perceptions of 
susceptibility to cervical cancer, and severity of abnormal Pap results as conveyed by a medical 
provider predicting perceived benefits to follow-up care, as well as one positive path from 
perceived benefits predicting receipt of follow-up care) remained significant only among White 
women, while three of these paths (i.e., positively related paths from severity of abnormal Pap 
results as conveyed by a medical provider  and ethnic centrality predicting perceptions of 
severity of cervical cancer; and perceptions of susceptibility to cervical cancer predicting receipt 
of follow-up care) remained significant only among Black women.  
For the present analysis, two new paths from doctor recommendation to obtain follow-up 
care positively predicting perception of benefits and negatively predicting perception of barriers 
to obtaining follow-up care were added to the model. These paths were relaxed, and were found 
only to be significant among White women.  
Exploratory Outcomes. Although doctor recommendation to obtain follow-up care after 
receiving an abnormal Pap result was not initially included as a variable in the hypotheses for 
this project, analyses conducted early on in the project indicated that it was an important variable 
to consider in attempting to model follow-up care decision-making processes for both groups of 
women. For White women, doctor recommendation was related to increased perceptions of 
benefits to obtaining follow-up care and decreased perceptions of barriers to obtaining follow-up 
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care. Although the influence was stronger among Black women, doctor recommendation was 
also related to an increased likelihood of obtaining follow-up care after an abnormal Pap result 
was received for both groups. This path additionally represented the strongest variable 
relationship in the model across both racial groups. The inclusion of these three variable paths 
into the model improved the overall amount of variance accounted for in receipt of follow-up 
care by 29.7 and 15.9 percentage points for Black and White women, respectively.  
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Figure 13.1. Path model showing the final invariant model for the exploratory hypothesis. Solid line arrows represent significant 
constrained paths that did not show moderation by race. Dashed arrows represent paths that were relaxed/ moderated by race.  
*p<.05, **p<.01, ***p<.001, ns = not significant 
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Figure 13.2. Path model showing model paths that were significant for White women. Line arrows represent significant constrained 
paths that did not show moderation by race. Dashed arrows represent paths that were relaxed/ moderated by race. 
*p<.05, **p<.01, ***p<.001 
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Figure 13.3. Path model showing model paths that were significant for Black women. Line arrows represent significant constrained 
paths that did not show moderation by race. Dashed arrows represent paths that were relaxed/ moderated by race. 
*p<.05, **p<.01, ***p<.001 
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Discussion 
The primary goal of the present research was to address significant gaps in the literature 
regarding disparities in cervical cancer diagnosis and mortality among Black women. Because 
Pap screening behavior has been extensively assessed without major improvements in disparate 
rates of diagnosis and mortality among Black women, this project pivots the research frame of 
interest to receipt of follow-up care after receiving an abnormal Pap result. Although decision-
making and healthcare-seeking behaviors related to Pap screening among Black women have 
been studied and prior work has determined that Black women are less likely than other racial 
groups to receive follow-up care (Fleming et al., 2014; Sharma et al., 2012), specific factors 
influencing decisions to receive cervical cancer follow-up care among this population had not 
been formally studied. 
This is the first study to use path modeling and model invariance analyses to provide a 
thorough evaluation of how various factors may be associated with Black women’s decision-
making processes related to obtaining cervical cancer screening and necessary follow-up care 
after an abnormal result. This method of analysis provides the ability to thoroughly examine 1) 
how various factors as defined by previous literature and operationalized through the HBM may 
be associated with Pap screening behavior, as well as receipt of recommended follow-up care 
following receipt of abnormal Pap results, 2) whether the aspects of care serving as significant 
factors in the path model assessing associations with Pap screening behavior for each racial 
group are similarly associated with receipt of recommended follow-up care, 3) whether the 
factors significantly influencing the decision-making processes for receipt of both types of 
cervical cancer care differ between Black and White women, and 4) whether ethnic centrality 
influences the overall cervical cancer follow-up care decision-making process for Black women.  
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Hypotheses 1a-b.  
 Hypotheses 1a and b examined differences in health service use related to cervical cancer 
prevention and treatment based on racial group. Across racial groups, the majority of participants 
reported having ever received a Pap smear, as well as receiving a Pap smear within the last 3 
years. Findings from hypothesis 1a show that White women were more likely to report ever 
having received Pap screening in their lifetime. However, results also showed that among those 
who reported having ever received a Pap screening, Black women were more likely to have 
received screening within the last 3 to 5 years, as is currently recommended by medical 
guidelines. These findings do not provide direct support for existing statistics showing that Black 
women are obtaining Pap screening at equal rates to those of White women (ACS, 2016). 
Instead, these findings may suggest that Black women are still experiencing disparities in 
cervical cancer screening initiation, and further suggest that once Black women do begin 
screening, they are more likely to continue receiving this preventive care at medically 
recommended intervals.  
These findings may provide support for the various programs and media campaigns that 
have been aimed at increasing rates of Pap screening among Black women, as it is possible that 
these programs have contributed to the rates of continued care that are seen here. Results also 
suggest that these program efforts would be particularly beneficial when aimed toward 
increasing initiation of Pap screening among Black women. In line with previous literature 
(Johnson et al., 2016; Tracy et al., 2013), Black women of all ages may additionally benefit from 
their medical providers engaging in ongoing conversations and education about cervical cancer 
health and the importance of initiating and continuing preventive screening. 
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While initial analyses for hypothesis 1b revealed racial disparities in follow-up care 
service use after receiving an abnormal Pap result, with White women being more likely to 
obtain care, further examination revealed more nuanced relationships. Additional analyses run to 
compare instances of doctor recommendation of follow-up diagnostic testing or treatment 
services between racial groups showed that White women were more likely than Black women to 
report that their provider had recommended obtaining follow-up services. This result was found 
among those who had received an abnormal Pap result of any severity level (96.7% of White 
women vs. 91.8% of Black women), and was even further exaggerated when evaluating only 
those who had received an abnormal Pap result of higher severity (i.e., where those reporting 
ASC-US and unknown abnormal results were excluded from analysis; 90.7% of White women 
vs. 70.4% of Black women). Interestingly, when looking only at those women who reported 
receiving doctor recommendations for follow-up care, Black and White women were equally 
likely to have obtained the care that their provider recommended.  
These results suggest that doctor recommendation is particularly influential when 
evaluating racial disparities in follow-up care receipt. Results may indicate that some medical 
providers are not appropriately recommending follow-up care, or that they are not effectively 
communicating information about abnormal Pap results and appropriate next steps with their 
Black patients. The latter possibility is supported in prior work that has shown confusion about 
or trouble remembering providers’ statements about their abnormal Pap results and necessary 
follow-up care (Bellinger et al., 2015). This supports previous work showing that Black women 
are less likely to have access to high quality care, which is likely to subsequently influence the 
quality and appropriateness of treatment following the receipt of abnormal Pap results (Hicks et 
al., 2006; Weragoda et al., 2016).  
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These findings may also reflect underlying racial differences in where health services are 
being obtained, as other work has reported that Black women are more likely to seek their 
cervical cancer care from primary care providers or emergency departments, while White women 
are more likely to seek care from gynecologists (Waknine, 2005). It is probable that providers 
who are reproductive health specialists, such as gynecologists, will be more familiar with 
medical guidelines and recommendations following abnormal Pap results than providers who are 
primarily focused in general medicine. If providers are not following medical guidelines for 
handling abnormal Pap results and follow-up care, additional training for providers that educates 
about these medical guidelines and provides a focus on effective communication of screening 
results and suggested follow-up tests or treatment could be beneficial for both medical providers 
and patients in improving health outcomes.  
Hypotheses 2a-f. 
 The second group of hypotheses examined the utility of the HBM in predicting Pap 
screening behavior for Black and White women. Previous work has studied some of the factors 
of the HBM individually to determine how they relate to cervical cancer disparities and 
screening behavior (Bellinger et al., 2015; Parrish, 2016; Strohl et al., 2015; Wong et al., 2013; 
Wong et al., 2014). The present study sought to evaluate how each of the HBM factors related to 
Pap screening behavior, and to determine whether different facets of the model were 
differentially influential for Black versus White women (i.e., whether the HBM factors that were 
most influential in decision-making were different for Black women versus White women). 
Present findings indicate some similarities between Black and White women on the impact of 
HBM factors, as well as some important differences.  
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 Similarities found between the groups include education not being significantly related to 
Pap screening, as well as insurance status being positively and the perception of barrier to 
screening being negatively related to screening behavior. In addition to being significant across 
both racial groups, the relationship between perceived barriers predicting engagement in Pap 
screening was also the strongest relationship present in the model for both groups, while the 
relationship between insurance status and perceived barriers was the second strongest.  
These findings support existing research showing that lack of insurance coverage, 
inadequate insurance coverage, and the presence of other barriers (e.g., being able to take time 
off from work, securing childcare in order to go to a doctor) are related to lower rates of 
preventive service use among women, regardless of racial group (Bellinger et al., 2015; Kaiser 
Family Foundation [KFF], 2013). Similarly, a nationally representative study not limited to 
women showed that only 33% of uninsured individuals – versus 67% of those with Medicaid and 
74% of those privately insured – received preventive screenings (Garfield et al., 2014). Because 
women are more likely to experience gaps in health insurance coverage due to their increased 
likelihood of being employed part-time, being covered as a dependent on a partner’s plan, and 
being of lower SES (KFF, 2013), insurance coverage is a particularly influential factor in 
preventive screening behavior. Considering that Kaiser Family Foundation (2013) has found that 
53% of uninsured women resided below 138% of the FPL, these findings will maintain their 
importance as some states continue in their refusal to expand Medicaid coverage.  
 Differences in HBM structure between Black and White women include the following: 
perceptions of personal susceptibility to cervical cancer were only influential in predicting Pap 
screening for Black women; perceptions of benefits to receiving Pap screening were only 
significant in predicting screening for White women; and while perceptions of cervical cancer 
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severity significantly predicted screening behavior for those in both racial groups, this 
relationship was more influential for Black women. Previous work has highlighted lack of 
knowledge among Black women related to cervical cancer, their increased risk for mortality 
from cervical cancer, and how to prevent it (Parrish, 2016). Present findings that perceptions of 
susceptibility to cervical cancer and severity are influential for Black women, while benefits of 
screening are not, may add a degree of nuance to this work, as well as to research and 
community programming focused on promoting such education among Black women in efforts 
to increase screening (Strohl et al., 2015). 
Hypotheses 3a-g. 
 The third set of hypotheses built upon the HBM constructed in hypotheses 2a-f to analyze 
the role of these same factors in predicting engagement in follow-up care after receiving an 
abnormal Pap result. This model included the addition of a factor representing the severity of the 
abnormal Pap result received as conveyed by a medical provider. Although it had yet to be 
formally researched, prior work suggested that disparities in cervical cancer diagnosis and 
mortality rates between Black and White women were likely due to disparities in follow-up care 
attainment and/ or quality between the groups (Bernard et al., 2012; Brandt et al., 2006; DeSantis 
et al., 2013; Horner et al., 2011; Weragoda et al., 2016). Additional work has also shown that 
Black women obtain follow-up care at the lowest rates of any racial group (Fleming et al., 2014; 
Sharma et al., 2012). Because prior work showed that certain experiences and motivations 
related to Pap screening behaviors are different for Black versus White women, it was 
hypothesized that the decision-making process for obtaining follow-up care after receiving an 
abnormal Pap result would also differ by racial group. Due to previous work indicating that 
doctor recommendation and effective communication between providers and patients (Ackerson, 
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2010; Bazargan et al., 2004) are important influences in obtaining Pap care (Johnson et al., 2016; 
Tracy et al., 2013), it was additionally hypothesized that the severity of Pap results as conveyed 
by a medical provider would be an influential factor in this decision-making process, in that if 
would increase perceptions of cervical cancer susceptibility and severity.  
 Partial support was found for this collection of hypotheses, and present results noted 
many similarities and differences between racial groups. For both groups, perceptions of cervical 
cancer severity and benefits to obtaining follow-up care decreased as age increased. This result 
may be related to previous work that has found that some women do not feel they need follow-up 
care because they believe that if something were wrong with their cervix then they would notice 
or feel it (Ackerson, 2010; Bellinger et al., 2015). This feeling of knowing what is normal or 
abnormal for one’s body and reproductive system are likely to increase with age and life 
experience. Regardless of the reasoning, though, these results may point to increased need for 
campaigns aimed at educating older women about the influences of cervical cancer and the 
benefits of obtaining follow-up care.  
 Another similarity between the groups was the finding that increases in duration of health 
insurance coverage for the previous year were related to decreased perceptions of barriers to 
follow-up care, as well as an increased likelihood of obtaining follow-up care after receiving an 
abnormal Pap result. These findings support previous literature outlined in the discussion of H1 
outcomes showing lack of health insurance as a barrier to receiving various types of needed 
healthcare services (KFF, 2013), and echo prior work noting the importance of access to quality 
health insurance to cover medical costs (Garfield et al., 2014; Sung, Alema-Mensah, & 
Blumenthal, 2002).  
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 Perceptions of barriers to follow-up testing were equally influential across racial groups, 
as well, and showed that as perceptions of barriers increased, the likelihood of obtaining follow-
up care decreased. Prior work supports this finding, and has noted various types of barriers to 
obtaining Pap care services, ranging from tangible resources (e.g., distance to a provider, 
transportation and childcare needs, difficulties in taking time off work; KFF, 2018; Ladoceour, 
2010; Nolan, et al., 2014) to emotional barriers (e.g., fear of harmful results, fear of pain, 
embarrassment, feeling unable to prevent cervical cancer from continuing to develop; Bellinger 
et al., 2015). Present results support more recent initiatives to reduce tangible barriers for those 
seeking care, such as the presence of daycare in doctor’s offices (Massachusetts General 
Hospital, 2019; Providence Health & Services, 2019) and Medicaid programs providing 
transportation to and from doctor’s appointments as a benefit of coverage (Centers for Medicare 
& Medicaid Services [CMS], 2016).  
Based on review of the items comprising the perceived barriers measure, and the 
inclusion of emotion-related barriers, present results may support the need for additional focus 
on evaluating emotional barriers and their role in influencing this decision-making process. 
Because of this emotional focus, support is also provided by present results for initiatives aimed 
at improving patient-provider communication of results and engagement in shared decision-
making with patients about their care (Ackerson, 2010; Bazargan et al., 2004; Bellinger et al., 
2015). Future work in this area should include the investigation of this relationship more closely 
so that education and training of providers can include direction on how best to approach 
conversations of abnormal results so that patients’ perceived barriers are addressed. 
 While the influence of perceived barriers to follow-up was significant for both groups, 
this influence was more strongly related to obtaining Pap screening than it was to receiving 
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follow-up care after an abnormal Pap, which was counter to hypotheses. This could be due to a 
number of factors; however, common threads may be patient-provider communication and 
professional connection to resources. The reduced influence of perceived barriers to follow-up 
may, in part, be due to the existence of programs intended to cover costs related to diagnostic 
and treatment care after receiving abnormal Pap results, such as Every Woman’s Life (EWL). 
EWL covers reproductive cancer screenings for women aged 40-64 who meet financial and 
residential qualifications, and will additionally cover follow-up care for women who are 18 or 
older, have received an abnormal Pap test, and meet qualifications (Every Woman’s Life, 2019). 
Unlike experiences with scheduling Pap screening tests, patients are contacted directly by 
providers about the need to schedule follow-up care. This contact offers an opportunity to 
provide insight that is usually missing when seeking Pap screening, such as financial resources 
that may exist, specialist provider options, what to expect from follow-up testing or treatment, 
and likely chain of events subsequent to follow-up care. If this information is provided, it may 
serve to reduce the influence of barriers in follow-up decision-making. 
The final similarity noted across groups was that of increased severity of an abnormal 
Pap result as conveyed by a medical provider being related to an increase in perceptions of 
susceptibility to cervical cancer. Although not explicitly studied in previous literature, it is 
reasonable that a doctor’s statement about the severity of abnormal cells found through one’s Pap 
screening would increase their feelings of susceptibility to developing cervical cancer from those 
cells in the future. This may be particularly important for providers to be aware of when 
communicating results with patients who are Black women, as perceived susceptibility to 
cervical cancer was only influential in predicting engagement in follow-up care for this group, 
and served as the most influential factor in the model for Black women. Even with a lack of 
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research evaluating engagement in cervical cancer follow-up care, these findings bear 
resemblance to previous work focused on Pap screening behavior that has noted a relationship 
between perceived susceptibilities predicting engagement in Pap screening (Parrish, 2016; Strohl 
et al., 2015). Thus, tapping into perceived susceptibility when discussing Pap results may serve 
as a unique motivating factor for receiving follow-up care among Black women.   
There were a few other paths that differed between racial groups, as well. Severity of 
abnormal Pap results as conveyed by a medical provider only predicted perceptions of cervical 
cancer severity among Black women. Interestingly, though, perceived severity did not 
significantly predict receipt of follow-up care for either racial group. These results indicate that 
although emphasizing the severity of one’s abnormal Pap results may increase perceptions of 
cervical cancer severity, this may not be beneficial, as perceptions of cervical cancer severity are 
not predictive of follow-up service use. Thus, these findings support limiting emphasis on 
severity in working toward the goal of improving engagement in follow-up care.  
Conversely, perceptions of benefits to follow-up care predicted receipt of follow-up care 
only among White women. This may be related to previous literature which has evaluated Black 
women’s perceptions of abnormal Pap results, and shown common discussions around fear that 
follow-up testing will show unwanted results that may require treatment that could reduce or 
eliminate fertility, or the belief that they would know if something were wrong with their bodies 
(i.e., they would be experiencing noticeable symptoms; Ackerson, 2010; Bellinger et al., 2015). 
The relationship of perceived benefits was also more influential for predicting receipt of follow-
up care for White women than it was in predicting Pap screening behavior. This may make sense 
in that Pap smears are commonly regarded as routine care where one expects to receive a null 
result confirming that there are no problems, while any follow-up care for an abnormal Pap result 
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is used to search for a false positive in the initial Pap result or to determine how severe cervical 
dysplasia is and what treatment will be necessary moving forward. Ergo, follow-up care may be 
seen as more beneficial in ruling out the presence of abnormal cells or preventing cervical cancer 
development. 
Although not part of the originally hypothesized model, analyses suggested adding paths 
from severity of an abnormal Pap result as conveyed by a medical provider predicting perceived 
benefits and barriers to follow-up care. These paths were found only to be significant for White 
women, and showed that as the doctor’s communication of Pap results portrayed increased 
severity, perceptions of benefits to follow-up care decreased and perceptions of barriers to 
follow-up care increased. Taken in sum with the rest of the model results, this may suggest that 
medical providers’ communication of the severity of abnormal results may result in substantial 
amounts of fear of cervical cancer diagnoses. Fear, related to physical and emotional 
experiences, has been discussed in some previous literature as a barrier to continued cervical 
cancer testing and care (Ackerson, 2010; Bellinger et al., 2015). It is possible that some patients 
interpret their abnormal results as being equivalent to a cervical cancer diagnosis during these 
communications, rather than being abnormal growth that is likely able to be controlled and 
eliminated with early intervention.  
If so, this may provide an explanation for why provider communication of severity of 
abnormal Pap results and perceptions of cervical cancer severity do not function as expected 
within the model. For instance, the introduction of fear of imminent cervical cancer diagnosis 
could explain why perceptions of cervical cancer severity are not predictive of engagement in 
follow-up care for either racial group, as well as why provider communication of Pap results is 
related to increased perceptions of cervical cancer susceptibility for both groups. Combined with 
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racial differences, this may additionally provide rationale as to why provider communication of 
Pap results is related to increased perception of cervical cancer severity for Black women, as 
well as increased perception of barriers and decreased perception of benefits for White women.   
Hypotheses 4a-c. 
 The goal of the final set of hypotheses was to determine the role, if any, of ethnic 
centrality in decisions to obtain follow-up care after receiving an abnormal Pap result. Previous 
work evaluating decisions among Black women to obtain Pap screening indicated that the 
salience of one’s ethnic identity was influential (Bellinger et al., 2015). However, in their work, 
the salience of ethnic identity was found to serve as both a protective and predictive factor of Pap 
screening among different women. Some Black women reported apprehension in receiving care 
for fear of receiving abnormal results that would require fertility-compromising treatment to 
correct, while others evoked the Strong Black Woman schema to explain their felt need to put 
the health and needs of others before themselves. Still others related the Strong Black Woman 
schema to their feelings that their identity was tied to a need to take care of themselves so that 
they may care for others, as well as a responsibility to educate others about testing (Bellinger et 
al., 2015).  
 Present results provided no support for the first parts of hypothesis 4, which evaluated the 
role of ethnic centrality as a moderator in the relationships between (a) perceived susceptibility 
and (b) severity of cervical cancer and obtaining follow-up care. However, the analyses did 
indicate that ethnic centrality was significantly related to both perceived susceptibility and 
severity for both racial groups. As a result, ethnic centrality was entered into the overall HBM 
model and tested as a predictor of both perceived susceptibility and severity, rather than as a 
moderator.  
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In the overall model, ethnic centrality did not predict perceptions of susceptibility to 
cervical cancer for either group, and predicted perceptions of cervical cancer severity among 
Black – but not White – women. This latter relationship showed that as feelings of ethnic 
centrality increased, perceptions of the severity of cervical cancer increased. However, as 
indicated above, perceived severity of cervical cancer was not significantly related to receipt of 
follow-up care for either racial group. Further, although not originally hypothesized, 
modification indices suggested that a path be added between ethnic centrality and perceived 
benefits of follow-up care. Interestingly, although it was more influential for Black women, this 
path was significant for both racial groups, and indicated that higher levels of ethnic centrality 
were related to increased perceptions of benefits to obtaining follow-up care.  
Taken together, these findings suggest that the salience of Black women’s ethnic identity 
plays a role in increasing perceptions of the severity of cervical cancer and the benefits provided 
by obtaining follow-up care after an abnormal Pap result; but that, ultimately, because neither 
perceived severity nor benefits represent a significant influence in Black women’s decision to 
receive follow-up care, a significant influence of ethnic centrality in this decision-making 
process was not found. Thus, although ethnic centrality was included in this model in an attempt 
to account for a portion of the decision-making process for Black women, it did not provide any 
additional insight in its current form. However, reflecting upon the findings of Bellinger and 
colleagues (2015), participants’ experiences of their ethnic identity may be interpreted as being 
heavily intertwined with their feminine identity, as they frequently discuss fears related to 
potential loss of fertility and the importance of being able to one day enter into or maintain their 
current role(s) as a mother, caretaker, or otherwise matriarchal presence. Thus, it may be 
beneficial for future work to incorporate salience of feminine identity or womanhood and 
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fertility into this decision-making process along with salience of ethnic identity in order to glean 
insight into how identification with specific identities may influence the emotional factors at play 
in the process of deciding to receive follow-up care.  
Additional differences between the final invariant model for H3 and the present model 
included relaxing the path from age predicting perceived benefits of follow-up care and 
constraining the path from severity of abnormal Pap results as conveyed by a medical provider 
predicting perceived barriers to follow-up care. For the first change, model indices suggested that 
the model would be stronger if this path were relaxed, and resulted in this path between age 
negatively predicting the perception of benefits to follow-up care only being significant among 
White women. The latter change resulted from model values indicating similarities between 
groups, and showed that increased severity of abnormal Pap results as conveyed by a medical 
provider was related to increased perception of barriers to follow-up care across racial groups. 
As discussed previously, this finding may indicate that when discussing abnormal Pap results 
with patients, a heavy focus on the severity of the abnormal Pap results may result in the 
opposite of the intended effect – where patients come to perceive even more barriers to receiving 
follow-up care, and may experience an increase in emotional barriers as they feel more fear 
around having additional testing done or learning the results of diagnostic testing. Thus, current 
results indicate that to improve engagement in follow-up care, it may be beneficial for providers 
to reduce the conversational focus on result severity, while placing more focus on assessing 
patient perception of barriers to receiving necessary follow-up care and assisting patients in the 
removal of these barriers.  
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Exploratory Analyses.  
 Due to previous work indicating that cues to action from medical providers have been 
found to increase rates of Pap screening (Bazargan, 2004; Bellinger et al., 2015), an exploratory 
chi square was conducted as part of hypothesis 1 to determine whether doctor recommendation 
influenced the disparities seen in rate of follow-up care attainment between racial groups. 
Because this analysis showed that accounting for doctor recommendation to receive follow-up 
care made rates of follow-up care receipt equal across Black and White women, it appeared to be 
an important factor to be included in the overall model to aid in the explanation of this decision-
making process for both racial groups. 
 The final invariant model for H4c was used to build the baseline model for these 
analyses, and was modified to include the factor of doctor recommendation to receive follow-up 
care. In the final invariant model for this exploratory analysis, three paths with doctor 
recommendation as the predictor were significant. Altogether, the inclusion of doctor 
recommendation as a factor in the path model accounted for an additional 30 and 16 percent of 
the variance in follow-up care decision-making among Black and White women, respectively. 
Doctor recommendation was a significant direct predictor of follow-up care receipt among both 
racial groups, and this path served as the most influential path in the model for each group. 
The other two paths emanating from doctor recommendation were only significant 
among White women, and indicated that receiving a recommendation from a medical provider to 
obtain follow-up care was associated with increased perceptions of benefits and decreased 
perceptions of barriers to follow-up care. These results are promising, as they suggest that when 
doctors make recommendations for White women to obtain follow-up care, they may be 
discussing some of the benefits of these services and be addressing barriers that come up for 
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patients. When taking the entire model into consideration this becomes even more influential, as 
higher perception of benefits and lower perception of barriers to follow-up care are predictive of 
engagement in follow-up care among White women. Thus, doctor recommendation to receive 
follow-up care seems to be operating effectively through these channels to improve uptake of 
follow-up services among White women. 
 Conversely, doctor recommendation to receive follow-up care did not operate through 
any of the HBM facets in Black women’s decision-making processes. One possible explanation 
for this could be that doctor recommendations for care are operating through factors not 
represented in the HBM. Prior work has discussed the role of health locus of control in screening 
behavior among Black women, and has found that those who believe that healthcare 
professionals are responsible for their health are more likely to be up-to-date in their Pap 
screening (Bazargan et al., 2004). Decisions to obtain follow-up care may operate similarly, with 
those having an external locus of control being more likely to follow their doctor’s 
recommendations to receive care.  
Another possibility is that the types of messaging used by providers is too inconsistent to 
form relationships between the HBM variables that are present. While it may be reasonable to 
theorize that doctor recommendation could operate through factors such as perceived 
susceptibility, severity, benefits, and barriers, some providers may emphasize the benefits of 
receiving follow-up care more during conversations with patients, while others focus more on 
susceptibility to cervical cancer, and still others focus more on reducing barriers to continued 
care. Without consistency across providers in the types and focus(es) of messages used to 
recommend follow-up care, it is unreasonable to expect that significant associations between 
these factors would form. As previously noted, literature has shown that while White women are 
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likely to receive their primary care services from physician’s offices, Black women are more 
likely to receive care from clinics, hospital emergency departments, or outpatient facilities 
(Waknine, 2005). Because sources of care for Black women are more variable than they are for 
White women, it is likely that the types and focuses of messages their providers use when 
conveying screening results and recommendations for follow-up care are more varied, as well.   
Limitations and Future Directions 
 Despite overall support for some hypotheses, several limitations must be considered. One 
limitation was the use of a cross-sectional correlational design, which prevents drawing any 
causal inferences. This study also utilized a relatively small sample size of those who did not 
receive follow-up care (i.e., 106 out of 660 who had abnormal results), thus only a very small 
subset of Black and White women included in these analyses reported not receiving follow-up 
care (60 and 46, respectively).   
 Relying on self-reports of health behaviors and service receipt, which are likely to 
contain some measurement error, is also a limitation of the present study. Participants may not be 
able to accurately recall the frequency or timing of participation in health services, may not be 
able to recall titles of diagnoses and treatments accurately, and/ or may feel pressure to report 
receiving recommended preventive cervical health services (Bhandari & Wagner, 2006).  
 This sample was also more highly educated, with 68.95% having received education 
beyond high school. However, this sample also had insured rates of 89.49%, which mirrored 
current U.S. health insurance coverage rates (91.5% of citizens covered in 2018; U.S. Census 
Bureau, 2019a), and the $50,000 median income of the sample is lower than that reported by the 
census ($61,937; U.S. Census Bureau, 2019b). Still, generalizability of the sample may 
somewhat be limited. This demographic distribution is likely a byproduct of internet sampling, 
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another limitation of this study. Samples collected through online platforms are characterized by 
possessing more privilege in terms of access to the internet and other types of resources. Thus, 
the results of the present study likely represent the upper bounds of negative outcomes that may 
have much lower bounds for those with less privilege.  
Although Amazon Mechanical Turk has the ability to recruit a nationally representative 
sample, individuals are still in control of which studies they self-select into. Therefore, it is 
possible that those who decided to self-select into a study about women’s health services differ 
from the general population. 
 This study also did not assess sources of care, continuity of care, effectiveness of 
provider communication, the role of feminine identity/ womanhood and fertility, or health locus 
of control. Previous research has indicated that these factors may play an important role in 
decisions to engage in certain health services (Bazargan et al., 2004; Bellinger et al., 2015). 
Future studies should incorporate these variables alongside the others present in this study, as 
understanding the potential influence of each of these can serve to further inform beneficial 
focuses and methods for community and provider interventions. 
Of particular importance moving forward is understanding the influence of emotional 
barriers to follow-up care (e.g., fear of what follow-up results may show). Additional 
investigation should focus on the weight of emotional barriers to follow-up compared to more 
traditionally discussed barriers related to tangible resources (e.g., lack of access to providers, 
cost, lack of time). Understanding which aspects of perceived barriers are more influential is 
likely to offer further insight into how providers can tailor their messages to more effectively 
target specific concerns that function as barriers to continued care.  
 
98 
 
General Implications 
 While using self-report data is a limitation of this study, online surveying resulted in a 
geographically representative national sample of cisgender women, allowed for the recruitment 
of a large number of Black women, and provided insight into some of the factors that predict 
engagement in Pap screening and follow-up care for Black and White women after receiving an 
abnormal Pap result. A particularly important implication of the present study is that expanding 
knowledge and training among medical providers would likely be beneficial in increasing the 
rates at which providers recommend appropriate follow-up care for their Black patients, thereby 
increasing the utilization of follow-up care among Black women, generally.  
Although the indicator of doctor recommendation to seek follow-up care is based on 
participants’ perceptions and understanding, Black women as a group were still less likely to 
report having received a recommendation to get follow-up care. This finding may reflect that 
providers are less likely to recommend follow-up care to Black women. Alternatively, findings 
may the result of failed communication between providers and their patients, where the provider 
did recommend follow-up care but the message was not received by the patient. Previous 
qualitative literature evaluating follow-up service use among Black women has noted the 
presence of miscommunication between providers and patients, and the resulting delay or 
discounting of follow-up service use (Bellinger et al., 2015). Taken together with previous work, 
current findings provide support for an increase in funding and resources to educate providers 
about current relevant medical standards and guidelines for cervical care, as well as the 
disparities existing in provider recommendations for follow-up between racial groups.  
 However, the present research also suggests that one standardized method of 
communicating abnormal Pap results and the need for follow-up diagnostic tests or treatment 
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may not be equally effective for Black and White women. Instead, the focus of patient-provider 
communications about abnormal Pap results and recommended follow-up care should be tailored 
to include information indicated to be more influential for Black or White women, as 
appropriate. Present results support limiting discussion of points that serve to increase 
perceptions of cervical cancer severity, and to include a larger focus on reducing perceptions of 
barriers, for both racial groups. For patients who are White women, it may be more beneficial for 
providers to also focus the conversation around the benefits of receiving follow-up testing, while 
for Black women it may be more beneficial to focus a larger portion of the conversation around 
points that increase understanding of their personal susceptibility to cervical cancer. Thus, these 
findings support the provision of additional provider training related to effective communication 
with patients and the need for diverse messaging that speaks to different patients’ values and 
concerns. 
Results from the present study additionally indicate that messaging techniques that 
incorporate ethnic identity may serve to increase perceptions of the severity of cervical cancer, 
but may not be particularly beneficial in persuading Black women to engage in follow-up care. 
Conversely, specific doctor recommendation to obtain follow-up care is likely to be the most 
beneficial factor influencing engagement in continued care. Therefore, present findings support 
direct, specific communication from medical providers about which follow-up services should be 
obtained, what each test or treatment is designed to do, and a clear rationale for why this care is 
important.  
Finally, current results show that access to health insurance remains a significant 
predictor of engagement in Pap screening and follow-up care. Thus, this study provides support 
for continued policy efforts aimed at increasing access to high quality health coverage, as well as 
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efforts to improve coverage for follow-up diagnostic testing and treatment of cervical cell 
abnormalities. These results also lend support for continued development and funding of 
programs that improve access to care, such as those that provide financial resources outside of 
health insurance coverage for those in need of follow-up care. Such efforts have the potential to 
improve access follow-up diagnostic tests and treatments for those in need through the reduction 
of systemic barriers.  
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APPENDIX A: 
 
RESEARCH SUBJECT INFORMATION AND CONSENT FORM 
 
TITLE: Experiences with Women’s Health Services 
 
VCU IRB NO.: HM20014743 
 
PURPOSE OF THE STUDY  
The purpose of this research study is to examine the relationships between women’s perceptions, 
experiences, and the use of preventive reproductive health services. 
 
DESCRIPTION OF THE STUDY AND YOUR INVOLVEMENT 
If you decide to be in this research study, you will first be asked to respond to brief demographic 
items to ensure that you are eligible to participate. If you do not qualify for this study, you will 
be informed at this time. 
If you do qualify for this study, you will then be asked to complete several online survey 
measures asking you about your knowledge and beliefs pertaining to reproductive health care, 
your reproductive medical history, and health service use during the previous year.  
 
This study should take no longer than 30 minutes. All of your responses will remain confidential, 
so the answers that you provide will not be released to anyone. 
 
RISKS AND DISCOMFORTS 
Sometimes discussing personal health issues and behaviors can cause people to become 
embarrassed or upset. These questions should not elicit more discomfort than what you might 
experience in normal daily interactions. You may stop participating in the research at any time.  
If you become upset, you may contact the research team using the information at the end of this 
form. 
 
There is also a risk of a loss of confidentiality. However, to minimize this risk, we do not ask for 
any identifying information, nor will your user ID be linked to your data. 
 
BENEFITS TO YOU AND OTHERS 
You may not get any direct benefit from this study, but the information we learn from people in 
this study may help us better understand how people understand and utilize health services in the 
United States. 
 
COSTS 
There are no costs for participating in this study other than the time you will spend filling out the 
questionnaires. 
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COMPENSATION 
You will be compensated $0.75 for your participation in this research study. In order to receive 
compensation, you must correctly answer 5 out of 7 quality assurance questions that are 
randomly placed throughout the questionnaire. 
 
CONFIDENTIALITY 
Data are being collected only for research purposes. MTurk automatically collects participants’ 
IP addresses; however, we will not retain your IP address in our saved records or link your 
survey responses to your IP addresses in any saved databases, publications, presentations, or any 
other format. 
 
Information from the study and your consent to participate may be looked at or copied for 
research or legal purposes by Virginia Commonwealth University. What we find from this study 
may be presented at conferences or published in scholarly papers, but your name will not ever be 
used in these presentations or papers. Your answers will remain confidential, as we will discard 
your IP addresses before data is stored and we are not collecting your name or other identifiable 
information. 
 
COMPUTER USE 
If possible, please take this survey on your personal computer. 
 
VOLUNTARY PARTICIPATION AND WITHDRAWAL 
Your participation in this study is voluntary.  You may decide to not participate in this study. 
Choosing not to participate will result in no penalty or loss of benefit to which you are otherwise 
entitled. If you do participate, you may withdraw from the study at any time without penalty.  
 
QUESTIONS 
In the future, you may have questions about your participation in this study. If you have any 
questions, complaints, or concerns about the research, contact: 
 Dr. Eric Benotsch 
 808 W. Franklin St., #208 
 Richmond, VA 23284 
 E-mail:  ebenotsch@vcu.edu 
 Phone:  804-828-0133 
 
The researcher/study staff named above is the best person(s) to call for questions about your 
participation in this study.  
 
If you have any general questions about your rights as a participant in this study, you may 
contact: 
 Office for Research 
 Virginia Commonwealth University 
 800 East Leigh Street, Suite 3000 
 P.O. Box 980568 
 Richmond, VA  23298 
 Telephone:  804-827-2157 
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Contact this number to ask general questions, to obtain information or offer input, and to express 
concerns or complaints about research. You may also call this number if you cannot reach the 
research team or if you wish to talk with someone else.  General information about participation 
in research studies can also be found at 
http://www.research.vcu.edu/human_research/volunteers.htm. 
 
CONSENT 
I have been given the chance to read this consent form. I understand the information about this 
study. Questions that I wanted to ask about the study have been answered. By clicking “I agree” 
below, I am indicating that I understand this consent form and agree to participate. I also verify 
that I am 21 years of age or older and live in the United States. 
 
 I choose to participate in this study. 
 I choose to not participate in this study. 
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APPENDIX B:  
 
STUDY QUESTIONNAIRE 
 
Instructions: Please answer the following questions to the best of your ability: 
 
[Demographic questions that will be used to determine eligibility for participation in the study] 
[Page 1] 
1. What state do you currently live in? _____  
 
2. What is your age? ___ 
[If under the age of 18 or over the age of 65, the respondent will be filtered out of the survey] 
 
[Page 2] 
3. Are you of Hispanic, Latino/a, or Spanish origin? (select all that apply): 
a. Mexican, Mexican American, Chicano/a 
b. Puerto Rican 
c. Cuban 
d. Another Hispanic, Latino/a, or Spanish origin 
e. None 
 
4. Which race best describes you:  
• White American 
• Black American 
• Asian 
• American Indian or Alaskan Native 
• Native Hawaiian or Other Pacific Islander 
• Other________________ 
[If response is not ‘Black American’, the respondent will be filtered out of the survey] 
 
[Page 3] 
5. Which of the following best describes your sexual orientation? 
• Heterosexual/ Straight 
• Homosexual/ Gay/ Lesbian 
• Down-low 
• Same gender loving 
• Bisexual/ Bi 
• Omnisexual/ Pansexual 
• Demisexual 
• Asexual 
• Queer/ Questioning 
• Other _______________ 
 
116 
 
6. Which of the following best describes your gender? [Note: cisgender means identifying with 
the sex assigned to you at birth, while transgender means not identifying with the sex 
assigned to you at birth]: 
• Cisgender Male 
• Cisgender Female 
• Transgender Male 
• Transgender Female 
• Non-Binary/ Gender Non-Conforming 
• Agender 
• Other ____________ 
[If response is not ‘Cisgender Female’, the respondent will be filtered out of the survey] 
 
 
7. Thinking about the past year, which option best describes the amount of time that you had 
health insurance coverage?  
• I was not insured at all in the past year 
• I was insured for 1-6 months out of the last year   
• I was insured for 7-11 months out of the last year 
• I was insured for all 12 months of the last year 
 
IF ANY INSURANCE IN PAST YEAR, BRANCH TO: 
8. What type(s) of health insurance plan(s) have you had in the past year?   
• Private Insurance       
o (Includes: Plans through employers, federal employee plans, plans from the 
Marketplace, plans through parents, plans through universities)   
• Public Insurance       
o (Includes: Military insurance (Tricare), Medicaid, Medicare, veterans 
benefits)        
 
Cervical Cancer Screening History 
9. Have you ever had a Pap test/ Pap smear done? No Yes I don’t know 
IF YES OR I DON’T KNOW, BRANCH TO: 
a. When was the last time that you received a Pap test?  
[Even if you are unsure of the exact date, please provide your best estimate.] ___ 
 IF NO, BRANCH TO: 
b. Why haven’t you ever had a Pap smear done? 
   
10. Have you had a Pap test in the last 3 years?  No Yes I don’t know 
IF YES, BRANCH TO: 
a. How many times have you had a Pap test in the last 3 years? 
[Even if you don’t know the exact number, please provide your best estimate] ___ 
 
IF NO OR I DON’T KNOW, BRANCH TO: 
a. Have you had a Pap test in the last 5 years? No Yes I don’t know 
IF YES, BRANCH TO: 
a. How many times have you had a Pap test in the last 5 years? 
[Even if you don’t know the exact number, please provide your best estimate] ___ 
IF NO, BRANCH TO THE END OF THE BLOCK 
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HPV Screening History 
11. Have you ever had an HPV test?  No Yes I don’t know  
IF YES OR I DON’T KNOW, BRANCH TO: 
c. When was the last time that you received an HPV test?  
[Even if you are unsure of the exact date, please provide your best estimate.] ___ 
 IF NO, BRANCH TO THE END OF THE BLOCK 
 
12. Have you had an HPV test in the last 3 years? No Yes I don’t know 
IF YES, BRANCH TO: 
a. How many times have you had an HPV test in the last 3 years? 
[Even if you don’t know the exact number, please provide your best estimate]___ 
 
IF NO OR I DON’T KNOW, BRANCH TO: 
13. Have you had an HPV test in the last 5 years? No Yes I don’t know 
IF YES, BRANCH TO: 
a. How many times have you had an HPV test in the last 5 years? 
[Even if you don’t know the exact number, please provide your best estimate]___ 
IF NO, BRANCH TO THE END OF THE BLOCK 
 
HPV Vaccination History 
14. Have you received at least one dose of the HPV vaccine?    ___No ___Yes  ___I don’t know 
IF YES, BRANCH TO → 
a. How many doses have you received? Please enter a number. ______  
b. How old were you when you received the HPV vaccine? Even if you are unsure, 
please enter a numerical age that is your best guess. _____  
c. When was your last dose? Even if you are unsure, please enter a numerical date that is 
your best guess. __  
d. Was the decision to receive the HPV vaccine yours or did a parent decide to have you 
vaccinated when you were an adolescent? 
 ___I decided ___A parent decided ___I decided with my parent(s) ___I don’t know 
 
15. Has a doctor ever offered the HPV vaccine to you?   ___No  ___Yes  ___I don’t know 
    
16. Has a doctor ever suggested that you receive the HPV vaccine? ___No  ___Yes  ___I don’t know 
IF YES, BRANCH TO → 
1. How old were you when a doctor suggested that you receive the HPV vaccine? 
 
HBM Dimensions for Pap Screening 
Subscales from The Health Belief Model Scale for Cervical Cancer and the Pap Smear Test. 
Guvenc, G., Akyuz, A., Han Acikel, C. (2011). Health belief model scale for cervical cancer and 
Pap smear test: psychometric testing. Journal of Advanced Nursing, 67(2), 428-437. doi: 
10.1111/j.1365-2648.2010.05450.x. 
 
Perceived Susceptibility  
 Strongly 
Disagree 
Disagree Slightly 
Disagree 
Slightly 
Agree 
Agree Strongly 
Agree 
17. It is likely that I will get cervical cancer 
in the future 
      
18. My chances of getting cervical cancer in 
the next few years are high 
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19. I feel I will get cervical cancer sometime 
during my life 
      
 
Perceived Seriousness/ Severity 
 Strongly 
Disagree 
Disagree Slightly 
Disagree 
Slightly 
Agree 
Agree Strongly 
Agree 
20. The thought of cervical cancer scares me       
21. When I think about cervical cancer, my 
heart beats faster 
      
22. I am afraid to think about cervical cancer       
23. Please select ‘Agree’ for this item (QA)       
24. Problems I would experience with 
cervical cancer would last a long time 
      
25. Cervical cancer would threaten a 
relationship with my partner or spouse 
      
26. If I had cervical cancer my whole life 
would change 
      
27. If I developed cervical cancer, I would 
not live longer than 5 years 
      
Perceived Barriers 
 Strongly 
Disagree 
Disagree Slightly 
Disagree 
Slightly 
Agree 
Agree Strongly 
Agree 
28. I am afraid to have a Pap smear test for 
fear of a bad result 
      
29. I am afraid to have a Pap spear test 
because I don’t know what will happen 
      
30. I don’t know where to go for a Pap 
smear test 
      
31. I would be ashamed to lie on a 
gynecologic examination table and show 
my private parts to have a Pap smear test  
      
32. Having a Pap smear test takes too much 
time 
      
33. Having a Pap smear test is too painful       
34. Health professionals doing Pap smear 
tests are rude to women 
      
35. I neglect or cannot remember to have a 
Pap smear test regularly 
      
36. I have other problems more important 
than having a Pap smear test in my life 
      
37. I am too old to have a Pap smear test 
regularly 
      
38. There is no health center close to my 
house to have a Pap smear test 
      
39. If there is cervical cancer in my destiny, 
having a Pap smear test cannot prevent it 
      
40. I prefer a female doctor to conduct a Pap 
smear test 
      
41. I will never have a Pap smear test if I 
have to pay for it 
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Perceived Benefits 
 Strongly 
Disagree 
Disagree Slightly 
Disagree 
Slightly 
Agree 
Agree Strongly 
Agree 
42. If I have a Pap smear test regularly and 
the result is good, I don’t need to worry 
too much about cervical cancer 
      
43. Having regular Pap smear tests will help 
to find changes to the cervix before they 
turn into cancer 
      
44. If cervical cancer was found at a regular 
Pap smear test, its treatment would not be 
so bad 
      
45. I think that having a regular Pap smear 
test is the best way for cervical cancer to 
be diagnosed early 
      
46. Having regular Pap smear tests will 
decrease my chances of dying from 
cervical cancer 
      
 
HBM Dimensions Modified for Follow-Up Care 
Modified subscales from the Health Belief Model Scale for Cervical Cancer & the Pap Smear Test. 
 
Perceived Barriers 
 Strongly 
Disagree 
Disagree Slightly 
Disagree 
Slightly 
Agree 
Agree Strongly 
Agree 
47. I am afraid to have follow-up diagnostic 
tests done for fear of a bad result 
      
48. I am afraid to have follow-up diagnostic 
tests done because I don’t know what 
will happen 
      
49. I don’t know where to go for follow-up 
diagnostic tests 
      
50. Please select strongly disagree for this 
item. (QA) 
      
51. I would be ashamed to lie on a 
gynecologic examination table and show 
my private parts to have follow-up 
diagnostic tests 
      
52. Having follow-up diagnostic tests takes 
too much time 
      
53. Having follow-up diagnostic tests is too 
painful 
      
54. Health professionals doing follow-up 
diagnostic tests are rude to women 
      
55. I neglected or could not remember to 
have follow-up diagnostic tests done 
      
56. I have other problems in my life that are 
more important than having follow-up 
diagnostic tests  
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57. There is no health center close to my 
house to have a Pap smear test 
      
58. If there is cervical cancer in my destiny, 
having follow-up diagnostic tests cannot 
prevent it 
      
59. I prefer a female doctor to conduct 
follow-up diagnostic tests 
      
60. I will never have follow-up diagnostic 
tests if I have to pay for it 
      
 
Perceived Benefits 
 Strongly 
Disagree 
Disagree Slightly 
Disagree 
Slightly 
Agree 
Agree Strongly 
Agree 
61. Having treatment done after getting 
abnormal Pap results will help eliminate 
dangerous cells in the cervix before they 
turn into cancer 
      
62. If cervical cancer was found during 
follow-up tests after a Pap smear, its 
treatment would not be so bad 
      
63. I think that having diagnostic tests done 
after abnormal Pap results is a good way 
for cervical cancer to be diagnosed early 
      
64. Having treatment done after getting 
abnormal Pap results will decrease my 
chances of dying from cervical cancer 
      
 
Ethnic Centrality  
Fuligni, A. J., Witkow, M., & Garcia, C. (2005). Ethnic identity and the academic adjustment of 
adolescents from Mexican, Chinese, and European backgrounds. Developmental Psychology, 41, 
799–811. http://dx.doi.org/10.1037/0012-1649.41.5.799 
 
65. Please fill in:  
In terms of ethnic group, I consider myself to be: ____________________ 
 
Instructions: The next set of questions asks you about your ethnicity. Looking at the items 
below, please tell me how much you agree or disagree with each statement, thinking about how 
you felt during the past year 
 
 
How well do these statements describe you? 
Strongly 
Disagree 
Disagree Neither 
Agree or 
Disagree 
Agree Strongly 
Agree 
66. Overall, being a member of my ethnic group has 
very little to do with how I feel about myself. 
     
67. In general, being a member of my ethnic group is 
an important part of my self-image. 
     
68. Being a part of my ethnic group is an important 
reflection of who I am. 
     
69. Being a part of my ethnic group is important for 
my social relationships. 
     
70. All of my friends say that I would make an 
excellent rhinoceros. 
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71. Being a part of my ethnic group is important to my 
sense of what kind of person I am. 
     
 
72. My ethnicity is   
 (1) Asian or Asian American, including Chinese, Japanese, and others 
 (2) Black or African American  
 (3) Hispanic or Latino, including Mexican American, Central American, and others    
 (4) White, Caucasian, Anglo, European American; not Hispanic  
 (5) American Indian/Native American 
 (6) Mixed; Parents are from two different groups 
 (7) Other (write in): _____________________________________  
 
73. My father's ethnicity is: 
 (1) Asian or Asian American, including Chinese, Japanese, and others 
 (2) Black or African American  
 (3) Hispanic or Latino, including Mexican American, Central American, and others    
 (4) White, Caucasian, Anglo, European American; not Hispanic  
 (5) American Indian/Native American 
 (6) Mixed; Parents are from two different groups 
 (7) Other (write in): _____________________________________ 
 
74. My mother's ethnicity is: 
 (1) Asian or Asian American, including Chinese, Japanese, and others 
 (2) Black or African American  
 (3) Hispanic or Latino, including Mexican American, Central American, and others    
 (4) White, Caucasian, Anglo, European American; not Hispanic  
 (5) American Indian/Native American 
 (6) Mixed; Parents are from two different groups 
 (7) Other (write in): _____________________________________ 
 
Personal Health History - Abnormal Pap Test Results – Last Pap 
Instructions: Consider the last Pap test you had: 
75. Were the results of the Pap smear normal or abnormal?   
Normal Abnormal I don’t know 
 
76. More specifically, were your results: 
Result  Result Full Name Result Description 
1. Normal  No abnormal cells present 
2. ASC-US Atypical Squamous Cells of 
Undetermined Significance 
Abnormal cells have been found, but they may or 
may not be dangerous 
3. LSIL Low-Grade Squamous 
Intraepithelial Lesion 
Mildly abnormal cells 
4. ASC-H Atypical Squamous Cells, 
cannot exclude HSIL 
Changes have been found that raise concern for 
the presence of HSIL 
5. HSIL High-Grade Squamous 
Intraepithelial Lesion 
Abnormal cells that are more serious 
6. AGC Atypical Glandular Cells Changes have been found in glandular cells raise 
concern for the presence of precancer or cancer 
7. My Pap smear test was abnormal, but I don’t know what the result was 
8. I never got my Pap smear test results 
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IF NO ABNORMAL RESULT OR NEVER GOT PAP RESULTS, BRANCH TO ALL PAP TEST 
HISTORY (Personal Health History - Abnormal Pap Test Results – All Pap History): 
 
IF ABNORMAL PAP RESULT RECEIVED (B-G), BRANCH TO: 
77. When your doctor told you about your abnormal Pap results: 
Did the doctor state: No Yes I don’t 
know 
a. That the results were potentially harmful to your health?    
b. That you should receive follow-up care?    
c. That you needed to receive follow- up care?    
d. That they wanted you to have another Pap test done?    
e. That they wanted you to have tests other than another Pap test done?    
 
Did you feel: No Yes I don’t 
know 
a. That the results were potentially harmful to your health?    
b. That you should receive follow-up care?    
c. That you needed to receive follow- up care?    
d. That you should have another Pap test done?    
e. That you should have tests other than another Pap test done?    
 
78. What care did your doctor recommend after your abnormal Pap result? Please select all that apply. 
[checkbox options] 
a. None 
b. Receive Pap AND HPV testing in 5 years 
c. Receive a Pap test again in 3 years 
d. Receive a Pap test again in 12 months 
e. Colposcopy (uses microscope to look for abnormal cells) 
f. Biopsy (removing tissue/ cells to rest for abnormalities) 
g. LEEP procedure (uses a wire loop carrying electric current to remove abnormal cells) 
h. Conization (cuts a cone-shaped piece of tissue out to remove abnormal cells) 
i. Cryotherapy (uses liquid gas to freeze abnormal cells) 
j. Laser therapy (uses laser to remove abnormal cells) 
k. I don’t know 
 
79. What care did you receive after your abnormal Pap result? Please select all that apply. 
[checkbox options] 
a. None 
b. Receive Pap AND HPV testing in 5 years 
c. Receive a Pap test again in 3 years 
d. Receive a Pap test again in 12 months 
e. Colposcopy (uses microscope to look for abnormal cells) 
f. Biopsy (removing tissue/ cells to rest for abnormalities) 
g. LEEP procedure (uses a wire loop carrying electric current to remove abnormal cells) 
h. Conization (cuts a cone-shaped piece of tissue out to remove abnormal cells) 
i. Cryotherapy (uses liquid gas to freeze abnormal cells) 
j. Laser therapy (uses laser to remove abnormal cells) 
k. I don’t know 
 
IF ‘NONE’ SELECTED (OPTION A), BRANCH TO: 
80. Why did/ didn’t you decide to receive follow-up care?_______________ 
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IF RECEIVED ANY CARE FOLLOWING ABNORMAL RESULT (B-K), BRANCH TO: 
81. Later the doctor told you about your abnormal Pap results, about how long did it take for you 
to schedule an appointment to get follow-up care?  
a. I scheduled an appointment that same day 
b. A few days 
c. A few weeks 
d. A few months 
e. More than a few months 
 
82. After the doctor told you about your abnormal Pap results, about how long did it take for you 
to receive follow-up care?  
a. I received follow-up care that same day 
b. A few days 
c. A few weeks 
d. A few months 
e. More than a few months 
f. I did not receive follow-up care 
 
IF ‘I DID NOT RECEIVE FOLLOW-UP CARE’ IS SELECTED (F), BRANCH TO: 
83. Why did/ didn’t you decide to receive follow-up care?_______________ 
IF RECEIVED ANY CARE FOLLOWING ABNORMAL RESULT (A-E), BRANCH TO: 
84. What results did you receive from this care? 
Result  Result Full Name Result Description 
a. Normal  No abnormal cells present 
b. ASC-US Atypical Squamous Cells of 
Undetermined Significance 
Abnormal cells have been found, but they may or 
may not be dangerous 
c. LSIL/ 
CIN I 
Low-Grade Squamous 
Intraepithelial Lesion 
Mildly abnormal cells 
d. ASC-H Atypical Squamous Cells, 
cannot exclude HSIL 
Changes have been found that raise concern for 
the presence of HSIL 
e. HSIL High-Grade Squamous 
Intraepithelial Lesion 
Abnormal cells that are more serious 
f. CIN II  Moderately abnormal cells 
g. CIN III  Severely abnormal cells or carcinoma in situ 
h. AGC Atypical Glandular Cells Changes have been found in glandular cells raise 
concern for the presence of precancer or cancer 
i. AIS Adenocarcinmoa in Situ Cancer cells found in glandular tissue of the 
endocervix 
j. My follow-up test was abnormal, but I don’t know what the result was 
k. I never got my follow-up test results 
 
85. What care did your doctor recommend to you after you received this result? Please select all 
that apply. [checkbox options] 
a. None 
b. Receive Pap AND HPV testing in 5 years 
c. Receive a Pap test again in 3 years 
d. Receive a Pap test again in 12 months 
e. Colposcopy (uses microscope to look for abnormal cells) 
f. Biopsy (removing tissue/ cells to rest for abnormalities) 
g. LEEP procedure (uses a wire loop carrying electric current to remove abnormal cells) 
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h. Conization (cuts a cone-shaped piece of tissue out to remove abnormal cells) 
i. Cryotherapy (uses liquid gas to freeze abnormal cells) 
j. Laser therapy (uses laser to remove abnormal cells) 
k. Follow up with a specialist 
l. I don’t know 
 
86. Why did/ didn’t you decide to receive follow-up care?_______________ 
 
 
IF NO ABNORMAL PAP RESULT RECEIVED ON LAST PAP, BRANCH TO: 
Personal Health History - Abnormal Pap Test Results – All Pap History 
Instructions: Consider all of the Pap tests you have ever had: 
87. Have you ever had abnormal results?   No  Yes  I don’t know 
  
88. Please indicate all of the following results you have ever received: 
Result  Result Full Name Result Description 
1. Normal  No abnormal cells present 
2. ASC-US Atypical Squamous Cells of 
Undetermined Significance 
Abnormal cells have been found, but they may or 
may not be dangerous 
3. LSIL Low-Grade Squamous 
Intraepithelial Lesion 
Mildly abnormal cells 
4. ASC-H Atypical Squamous Cells, 
cannot exclude HSIL 
Changes have been found that raise concern for 
the presence of HSIL 
5. HSIL High-Grade Squamous 
Intraepithelial Lesion 
Abnormal cells that are more serious 
6. AGC Atypical Glandular Cells Changes have been found in glandular cells raise 
concern for the presence of precancer or cancer 
7. My Pap smear test was abnormal, but I don’t know what the result was 
8. I never got my Pap smear test results 
 
IF NORMAL, BRANCH TO END OF BLOCK 
IF ‘I NEVER GOT MY PAP SMEAR TEST RESULTS,’ BRANCH TO END OF BLOCK 
 
IF ABNORMAL PAP RESULT RECEIVED (B-G), BRANCH TO: 
89. When your doctor told you about your abnormal Pap results: 
Did the doctor state: No Yes I don’t 
know 
a. That the results were potentially harmful to your health?    
b. That you should receive follow-up care?    
c. That you needed to receive follow- up care?    
d. That they wanted you to have another Pap test done?    
e. That they wanted you to have tests other than another Pap test done?    
 
Did you feel: No Yes I don’t 
know 
f. That the results were potentially harmful to your health?    
g. That you should receive follow-up care?    
h. That you needed to receive follow- up care?    
i. That you should have another Pap test done?    
j. That you should have tests other than another Pap test done?    
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90. What care did your doctor recommend after your abnormal Pap result? Please select all that apply. 
[checkbox options] 
a. None 
b. Receive Pap AND HPV testing in 5 years 
c. Receive a Pap test again in 3 years 
d. Receive a Pap test again in 12 months 
e. Colposcopy (uses microscope to look for abnormal cells) 
f. Biopsy (removing tissue/ cells to rest for abnormalities) 
g. LEEP procedure (uses a wire loop carrying electric current to remove abnormal cells) 
h. Conization (cuts a cone-shaped piece of tissue out to remove abnormal cells) 
i. Cryotherapy (uses liquid gas to freeze abnormal cells) 
j. Laser therapy (uses laser to remove abnormal cells) 
k. I don’t know 
 
91. What care did you receive after your abnormal Pap result? Please select all that apply. 
[checkbox options] 
a. None 
b. Receive Pap AND HPV testing in 5 years 
c. Receive a Pap test again in 3 years 
d. Receive a Pap test again in 12 months 
e. Colposcopy (uses microscope to look for abnormal cells) 
f. Biopsy (removing tissue/ cells to rest for abnormalities) 
g. LEEP procedure (uses a wire loop carrying electric current to remove abnormal cells) 
h. Conization (cuts a cone-shaped piece of tissue out to remove abnormal cells) 
i. Cryotherapy (uses liquid gas to freeze abnormal cells) 
j. Laser therapy (uses laser to remove abnormal cells) 
k. I don’t know 
 
IF ‘NONE’ SELECTED (OPTION A), BRANCH TO: 
92. Why did/ didn’t you decide to receive follow-up care?_______________ 
 
IF RECEIVED ANY CARE FOLLOWING ABNORMAL RESULT (B-K), BRANCH TO: 
93. After the doctor told you about your abnormal Pap results, about how long did it take for you 
to schedule an appointment to get follow-up care?  
a. I scheduled an appointment that same day 
b. A few days 
c. A few weeks 
d. A few months 
e. More than a few months 
 
94. After the doctor told you about your abnormal Pap results, about how long did it take for you 
to receive follow-up care?  
a. I received follow-up care that same day 
b. A few days 
c. A few weeks 
d. A few months 
e. More than a few months 
f. I did not receive follow-up care 
 
IF ‘I DID NOT RECEIVE FOLLOW-UP CARE’ IS SELECTED (F), BRANCH TO: 
95. Why did/ didn’t you decide to receive follow-up care?_______________ 
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IF RECEIVED ANY CARE FOLLOWING ABNORMAL RESULT (A-E), BRANCH TO: 
96. What results did you receive from this follow-up care? 
Result  Result Full Name Result Description 
a. Normal  No abnormal cells present 
b. ASC-US Atypical Squamous Cells of 
Undetermined Significance 
Abnormal cells have been found, but they may or 
may not be dangerous 
c. LSIL/ 
CIN I 
Low-Grade Squamous 
Intraepithelial Lesion 
Mildly abnormal cells 
d. ASC-H Atypical Squamous Cells, 
cannot exclude HSIL 
Changes have been found that raise concern for 
the presence of HSIL 
e. HSIL High-Grade Squamous 
Intraepithelial Lesion 
Abnormal cells that are more serious 
f. CIN II  Moderately abnormal cells 
g. CIN III  Severely abnormal cells or carcinoma in situ 
h. AGC Atypical Glandular Cells Changes have been found in glandular cells raise 
concern for the presence of precancer or cancer 
i. AIS Adenocarcinmoa in Situ Cancer cells found in glandular tissue of the 
endocervix 
j. My follow-up test was abnormal, but I don’t know what the result was 
k. I never got my follow-up test results 
 
97. What care did your doctor recommend to you after you received this result? Please select all 
that apply. [checkbox options] 
a. Receive Pap AND HPV testing in 5 years 
b. Receive a Pap test again in 3 years 
c. Receive a Pap test again in 12 months 
d. Colposcopy (uses microscope to look for abnormal cells) 
e. Biopsy (removing tissue/ cells to rest for abnormalities) 
f. LEEP procedure (uses a wire loop carrying electric current to remove abnormal cells) 
g. Conization (cuts a cone-shaped piece of tissue out to remove abnormal cells) 
h. Cryotherapy (uses liquid gas to freeze abnormal cells) 
i. Laser therapy (uses laser to remove abnormal cells) 
j. Follow up with a specialist 
k. None 
l. I don’t know 
 
98. Why did/ didn’t you decide to receive follow-up care?_______________ 
 
Personal Medical History  
 No Yes 
99. Do you have a chronic health condition?     
100. Do you have an auto-immune disorder?   
101. Do you have a reproductive health issue?   
102. Have you ever been diagnosed with cervical cancer?   
103. Have you ever been diagnosed with breast cancer?   
104. Have you ever been diagnosed with ovarian cancer?   
105. Have you ever been diagnosed with any other form of cancer?   
 
106. Have you ever been treated for cervical cancer?  No Yes 
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IF YES, BRANCH TO: 
a. What type of treatment(s) did you receive for cervical cancer? [checkbox options] 
a. Surgery 
b. Radiation 
c. Chemotherapy 
d. Targeted therapy 
e. Immunotherapy 
f. I don’t know 
 
107. Have you had a hysterectomy?         ___No __Yes ___I don’t know 
IF YES, BRANCH TO: 
a. Did you have your cervix removed during your hysterectomy?   
      ___No __Yes ___I don’t know 
 
108. Were you exposed to DES while your mother was pregnant? No __Yes ___I don’t know 
 
109. Have you been diagnosed with HIV?          ___No __Yes  
 
Family Medical History 
Have any of your immediate family members (i.e., siblings, 
parents, aunts, grandparents) been diagnosed with: 
No Yes I don’t 
know 
110. Cervical cancer?    
111. Breast cancer?    
112. Ovarian cancer?    
113. Any other form of cancer?    
 
[Other demographic questions] 
114. How many people live in your household? ______ 
  
115. How many of the people living in your household are dependent children? ______  
 
116. Please report the amount that best describes your household yearly income BEFORE taxes 
(Note: this amount should include all income, including veterans’ payments, child support, 
alimony, and assistance from outside of the household; however, it should exclude food 
stamps and housing subsidies): ______ 
 
117. Highest level of education completed:  
• Middle school 
• High school 
• GED 
• Vocational school 
• Associates Degree 
• Bachelor Degree 
• Graduate Degree (Masters, Doctorate, etc.) 
 
118. Of the following, please choose the option that best describes your highest level of 
employment (e.g., if you have both a part-time and a full-time job, choose "full time"):   
• Not employed 
• Student 
128 
 
• Employed part-time 
• Employed full-time 
• Retired 
 
119. Relationship Status:  
• Not currently dating or in a relationship   
• In a newer relationship with 1 person (less than 12 months)  
• In a long-term relationship with 1 person (12 months or longer)  
• Married   
• Dating/ in a relationship with more than 1 person 
 
120. Which of the following best describes your gender? [Note: cisgender means identifying 
with the sex assigned to you at birth, while transgender means not identifying with the sex 
assigned to you at birth]: 
• Cisgender Male 
• Cisgender Female 
• Transgender Male 
• Transgender Female 
• Non-Binary/ Gender Non-Conforming 
• Agender 
• Other ____________ 
 
121. Which race best describes you:  
• White American 
• Black American 
• Asian 
• American Indian or Alaskan Native 
• Native Hawaiian or Other Pacific Islander 
• Biracial or Multiracial 
• Other________________ 
 
122. What do you think this survey is about? (QA) _____________________ 
 
123. Random code assignment. “Please type the code you see displayed here.” __________ 
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Appx C: 
U.S. Census Bureau State Region Designations 
REGION 1: NORTHEAST 
Division 1: New England Division 2: Middle Atlantic 
Connecticut (07) New Jersey (31) 
Maine (20) New York (33) 
Massachusetts (22) Pennsylvania (39) 
New Hampshire (30)   
Rhode Island (40)   
Vermont (46)   
 
REGION 2: MIDWEST 
Division 3: East North Central Division 4: West North Central 
Illinois (14) Iowa (16) 
Indiana (15) Kansas (17) 
Michigan (23) Minnesota (24) 
Ohio (36) Missouri (26) 
Wisconsin (50) Nebraska (28) 
  North Dakota (35) 
  South Dakota (42) 
 
REGION 3: SOUTH 
Division 5: South Atlantic Division 6: East South Central 
Delaware (08) Alabama (01) 
District of Columbia (09) Kentucky (18) 
Florida (10) Mississippi (25) 
Georgia (11) Tennessee (43) 
Maryland (21)   
North Carolina (34)   
South Carolina (41)   
Virginia (47)   
West Virginia (49)   
 
Division 7: West South Central 
  
Arkansas (04)   
Louisiana (19)   
Oklahoma (37)   
Texas (44)   
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REGION 4: WEST 
Division 8: Mountain Division 9: Pacific 
Arizona (03) Alaska (02) 
Colorado (06) California (05) 
Idaho (13) Hawaii (12) 
Montana (27) Oregon (38) 
Nevada (29) Washington (48) 
New Mexico (32)   
Utah (45)   
Wyoming (51)   
 
 
U.S. Census Bureau, Population Division. (2017). Census Bureau Region and Division Codes 
and Federal Information Processing System (FIPS) Codes for States, 2016. Available from: 
https://www2.census.gov/programs-surveys/popest/geographies/2016/state-geocodes-v2016.xls 
 
